Cockayne Syndrome

Genetic MONDO:0016006 Pathograph 12 DNA Repair Disorder Progeroid Syndrome Neurodevelopmental Disorder

Cockayne syndrome is an ultra-rare autosomal recessive multisystem DNA repair disorder caused primarily by ERCC6 or ERCC8 dysfunction. It is a segmental progeroid syndrome with defective transcription-coupled nucleotide excision repair (TC-NER), resulting in progressive neurodevelopmental and neurodegenerative manifestations, cachectic dwarfism, photosensitivity, and premature aging across multiple organ systems.

Ask OpenScientist

Ask a research question about Cockayne Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

Autosomal Recessive HP:0000007

Cockayne syndrome classically follows autosomal recessive inheritance due to biallelic pathogenic variants in DNA repair genes.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:39473441 SUPPORT Human Clinical

"BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal recessive disorder characterized by cachectic dwarfism, nervous system abnormalities, and premature aging."

Directly supports autosomal recessive inheritance in CS.

ORPHA:191 SUPPORT

"Autosomal recessive"

Orphadata confirms autosomal recessive inheritance for Cockayne syndrome.

◆

Subtypes

Cockayne syndrome type I

Classic form with onset in the first 1-2 years of life, progressive neurologic and systemic involvement, and death typically in the first or second decade.

Show evidence (1 reference)

PMID:38674442 SUPPORT Human Clinical

"Four patients had CS I, three patients CS II, and one patient CS III."

This cohort directly confirms clinical subtype stratification including type I.

Cockayne syndrome type II

Severe congenital or early-onset form with prenatal or neonatal manifestations, minimal neurologic development, and early lethality.

Show evidence (1 reference)

PMID:38674442 SUPPORT Human Clinical

"Our work confirms clinical variability also in the ERCC6/CSB type, where manifestations may range from severe involvement with prenatal or neonatal onset to normal psychomotor development followed by progressive ataxia."

Supports severe early-onset disease biology consistent with type II presentations.

Cockayne syndrome type III

Milder form with relatively later onset, less severe progression, and longer survival.

Show evidence (1 reference)

PMID:38674442 SUPPORT Human Clinical

"Four patients had CS I, three patients CS II, and one patient CS III."

Confirms type III within the observed ERCC6-related spectrum.

⚙

Pathophysiology

Defective Transcription-Coupled Nucleotide Excision Repair

Pathogenic ERCC6/ERCC8 variants impair transcription-coupled nucleotide excision repair (TC-NER), disrupting removal of transcription-blocking DNA lesions in actively transcribed genes. TC-NER is initiated by stalling of elongating RNA polymerase complexes at damaged sites.

transcription-coupled nucleotide-excision repair link

Downstream

Impaired Neural Progenitor Migration CSB-deficient iPSC-derived neural models exhibit impaired neural progenitor migration via defective autophagy, linking the upstream TC-NER defect to clinical microcephaly.

Impaired Oligodendrocyte Maturation CSB deficiency impairs oligodendrocyte maturation in iPSC-derived neural systems, providing a downstream cellular consequence of the underlying TC-NER defect that explains CNS demyelination.

Disturbed Developmental GABA Switch CSB deficiency in iPSC-derived neural models produces abnormal GABA neurotransmitter levels suggestive of a disturbed developmental GABA switch downstream of the underlying TC-NER defect.

NRF2 Pathway Repression CS fibroblasts show repression of the NRF2 oxidative-stress response pathway, identifying redox dysregulation as a downstream consequence of impaired TC-NER and DNA-repair-coupled transcription.

Arachidonic Acid Metabolism Activation CS fibroblasts show inflammatory activation of arachidonic acid metabolism downstream of impaired DNA-repair-coupled transcription.

Mitochondrial DNA Maintenance Deficiency Loss of CSA/CSB function leads to depletion of mitochondrial DNA polymerase gamma (POLG1), placing mitochondrial DNA maintenance deficiency downstream of the upstream TC-NER/transcription defect.

Epigenomic Acceleration of Aging CS fibroblasts develop a progeroid-specific DNA methylation signature that is absent in UV-sensitive syndrome (which shares the NER defect but lacks progeria), implicating CSA/CSB-dependent transcription functions as the upstream driver of accelerated epigenomic aging.

Peripheral Demyelinating Neuropathy Susceptibility The CS TC-NER defect renders long-lived myelinating Schwann cells vulnerable to unrepaired transcription-blocking DNA lesions, producing the characteristic demyelinating polyneuropathy phenotype.

Show evidence (3 references)

PMID:40723898 SUPPORT Other

"A branch of the nucleotide excision repair (NER) pathway, transcription-coupled repair (TCR or TC-NER) specifically operates on the template DNA strand of actively transcribed genes."

Defines the core repair pathway mechanistically affected in Cockayne syndrome biology.

PMID:40332372 SUPPORT Other

"TCR, a specialized sub-pathway of nucleotide excision repair, rapidly removes transcription-blocking lesions from the transcribed strand of active genes, thereby safeguarding transcription fidelity and cellular homeostasis."

Reinforces TC-NER as the critical pathway disrupted in CS, with consequences for transcription fidelity.

PMID:38674442 SUPPORT Human Clinical

"(1) Background: Cockayne syndrome (CS) is an ultra-rare multisystem disorder, classically subdivided into three forms and characterized by a clinical spectrum without a clear genotype-phenotype correlation for both the two causative genes ERCC6 (CS type B) and ERCC8 (CS type A)."

Provides direct human clinical-genetic evidence that ERCC6 and ERCC8 are the main causal genes.

Impaired Neural Progenitor Migration

CSB deficiency causes impaired neural progenitor cell migration due to defective autophagy, providing a mechanistic explanation for the microcephaly observed in Cockayne syndrome.

neural progenitor cell link

autophagy link

Show evidence (2 references)

PMID:39179905 SUPPORT In Vitro

"In our models, CSB deficiency is associated with (i) impaired cellular migration due to defective autophagy as an explanation for clinical microcephaly"

Directly links impaired migration via defective autophagy to microcephaly in CSB.

PMID:39179905 SUPPORT In Vitro

"Of note, the impaired migration and oligodendrocyte maturation could both be partially rescued by pharmacological HDAC inhibition."

Demonstrates pharmacological rescue potential for the migration defect, suggesting a targetable pathway.

Disturbed Developmental GABA Switch

CSB-deficient neurons show abnormal GABA neurotransmitter levels, suggestive of a disturbed developmental GABA switch that impairs brain circuit formation and causes intellectual disability.

neuron link

gamma-aminobutyric acid signaling pathway link

Downstream

Impaired Neuronal Network Formation The disturbed developmental GABA switch impairs brain circuit formation in CSB-deficient iPSC-derived neural models, directly producing altered neuronal network functionality.

Show evidence (1 reference)

PMID:39179905 SUPPORT In Vitro

"altered neuronal network functionality and neurotransmitter GABA levels, which is suggestive of a disturbed GABA switch that likely impairs brain circuit formation and ultimately causes intellectual disability"

Identifies disturbed GABA switch as a mechanism underlying intellectual disability in CSB.

Impaired Neuronal Network Formation

CSB-deficient neurons show altered network functionality in iPSC-derived 3D neural models, indicating impaired neuronal network formation.

neuron link

neurogenesis link

Show evidence (1 reference)

PMID:39179905 SUPPORT In Vitro

Demonstrates altered neuronal network functionality in CSB-deficient neural models.

Impaired Oligodendrocyte Maturation

CSB deficiency impairs oligodendrocyte maturation in human iPSC-derived 3D neural models, providing a mechanistic basis for the demyelination observed in Cockayne syndrome.

oligodendrocyte precursor cell link

oligodendrocyte differentiation link myelination link

Show evidence (1 reference)

PMID:39179905 SUPPORT In Vitro

"(iii) impaired oligodendrocyte maturation as a possible cause of the demyelination observed in children with CSB."

Directly links oligodendrocyte maturation failure to clinical demyelination.

NRF2 Pathway Repression

Cockayne syndrome fibroblasts show repression of the NRF2 oxidative stress response pathway, contributing to dysregulated redox homeostasis. This abnormality is partially reversible with nicotinamide supplementation.

fibroblast link

response to oxidative stress link

Downstream

Accelerated Cellular Senescence NRF2 pathway repression compromises antioxidant defenses and links oxidative stress to accelerated cellular senescence in CS fibroblasts.

Show evidence (2 references)

PMID:39611850 SUPPORT In Vitro

"Gene expression analysis revealed alterations in two main pathways. This involves the activation of arachidonic acid metabolism and the repression of the NRF2 pathway in affected individuals with CS."

Identifies NRF2 pathway repression as a key oxidative stress defect in CS fibroblasts.

PMID:39611850 SUPPORT In Vitro

"The supplementation with nicotinamide adjusted these abnormalities by enhancing autophagy and decreasing inflammation."

Demonstrates nicotinamide can partially rescue the NRF2-related abnormalities.

Arachidonic Acid Metabolism Activation

Cockayne syndrome fibroblasts show activation of arachidonic acid metabolism, contributing to inflammatory dysregulation. This abnormality is partially reversible with nicotinamide supplementation.

fibroblast link

arachidonate metabolic process link

Downstream

Accelerated Cellular Senescence Arachidonic acid metabolism activation drives chronic inflammatory signaling that contributes to accelerated cellular senescence in CS fibroblasts.

Show evidence (2 references)

PMID:39611850 SUPPORT In Vitro

Identifies arachidonic acid metabolism activation as a key inflammatory pathway perturbation in CS fibroblasts.

PMID:39611850 SUPPORT In Vitro

"The supplementation with nicotinamide adjusted these abnormalities by enhancing autophagy and decreasing inflammation."

Demonstrates nicotinamide can partially rescue the inflammatory abnormalities including arachidonic acid pathway activation.

Mitochondrial DNA Maintenance Deficiency

CS proteins participate in mitochondrial homeostasis. CSA/CSB deficiency leads to depletion of mitochondrial DNA polymerase gamma (POLG1), which can be restored by nicotinamide supplementation, linking nuclear DNA repair defects to mitochondrial dysfunction.

fibroblast link

mitochondrial DNA replication link

Downstream

Mitochondrial Dysfunction with Impaired Mitophagy POLG1 depletion compromises mitochondrial DNA maintenance and contributes to the broader mitochondrial dysfunction and impaired mitophagy phenotype seen in CS cells and tissues.

Show evidence (1 reference)

PMID:39611850 SUPPORT In Vitro

"CSA/CSB-dependent depletion of the mitochondrial DNA polymerase-γ catalytic subunit (POLG1) was restored following nicotinamide supplementation in CS-affected individuals' fibroblasts."

Demonstrates that CS proteins are required for mitochondrial DNA maintenance via POLG1, providing a mechanistic link between nuclear DNA repair defects and mitochondrial dysfunction.

Mitochondrial Dysfunction with Impaired Mitophagy

Cross-species transcriptomic and biochemical studies demonstrate that Cockayne syndrome involves mitochondrial dysfunction and compromised mitophagy/autophagy, contributing to accelerated cellular aging. Restoration of NAD+ levels through precursor supplementation rescues mitochondrial dysfunction in CS cellular and nematode models, identifying NAD+ signaling as a convergent target connecting DNA damage accumulation with mitochondrial failure.

fibroblast link

mitophagy link NAD+ biosynthetic process link

Downstream

Accelerated Cellular Senescence Mitochondrial dysfunction and impaired mitophagy drive accumulation of damaged mitochondria, oxidative stress, and energetic failure that converge on accelerated cellular senescence in CS.

Show evidence (2 references)

PMID:33166073 SUPPORT Model Organism

"Our cross-species transcriptomic analysis in CS postmortem brain tissue, CS mouse, and nematode models shows that mitochondrial dysfunction is indeed a common feature in CS."

Establishes mitochondrial dysfunction as a conserved pathogenic feature of CS across species and tissue contexts.

PMID:33166073 SUPPORT In Vitro

"In primary cells depleted for CSA or CSB, this dysfunction can be corrected with supplementation of NAD+ precursors."

Demonstrates rescue of mitochondrial defects via NAD+ precursor supplementation, supporting NAD+ signaling as a key mechanistic and therapeutic node.

Epigenomic Acceleration of Aging

Genome-wide DNA methylation profiling distinguishes Cockayne syndrome fibroblasts from those of UV-sensitive syndrome (which lacks the progeroid phenotype) and identifies a CS-specific epigenomic signature associated with accelerated biological age. The CS-specific differentially methylated genes are enriched in developmental transcription factors and synaptic neurodevelopmental programs.

fibroblast link

epigenetic regulation of gene expression link

Downstream

Accelerated Cellular Senescence The CS-specific progeroid epigenomic signature (advanced epigenetic age, reprogramming of developmental and synaptic gene programs) provides a molecular substrate for accelerated cellular senescence.

Show evidence (2 references)

PMID:37688320 SUPPORT In Vitro

"Differential analysis highlighted a CS-specific epigenomic signature (progeroid-related; not present in UVSS) enriched in three categories: developmental transcription factors, ion/neurotransmitter membrane transporters and synaptic neuro-developmental genes."

Identifies a progeroid-specific DNA methylation signature in CS that is absent in UV-sensitive syndrome, supporting an epigenomic mechanism for accelerated aging distinct from the shared NER defect.

PMID:37688320 SUPPORT In Vitro

"the epigenetic clock returned a marked increase in CS biological age respect to healthy and UVSS cells."

Quantifies accelerated biological aging in CS cells using an epigenetic clock, providing molecular evidence for the progeroid phenotype.

Peripheral Demyelinating Neuropathy Susceptibility

Peripheral nerve involvement is a recognized component of Cockayne syndrome, particularly demyelinating polyneuropathy, reflecting vulnerability of long-lived myelinating Schwann cells to unrepaired transcription-blocking DNA lesions.

Schwann cell link

myelination link

Show evidence (1 reference)

PMID:36190439 SUPPORT Human Clinical

"Cockayne syndrome has classically been linked to demyelinating polyneuropathies, whereas xeroderma pigmentosum has long been associated with axonal polyneuropathies."

Supports a characteristic demyelinating peripheral neuropathy profile in CS.

Accelerated Cellular Senescence

Cockayne syndrome is a segmental progeroid syndrome in which defective DNA repair leads to accelerated cellular aging. Oxidative stress and autophagy dysfunction contribute to cellular senescence observed across multiple organ systems.

cellular senescence link

Show evidence (2 references)

PMID:39611850 SUPPORT In Vitro

"Cockayne syndrome (CS) is a segmental progeroid syndrome characterized by defects in the DNA excision repair pathway, predisposing to neurodegenerative manifestations."

Directly classifies CS as a segmental progeroid syndrome.

PMID:39611850 SUPPORT In Vitro

"This study reveals the link between oxidative stress and accelerated aging in affected individuals with CS and highlights new biomarkers of cellular senescence."

Supports the mechanistic link between oxidative stress and accelerated cellular senescence in CS.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 1

Hypertension OCCASIONAL Hypertension (HP:0000822)

Hypertension is reported in approximately 18% of CS patients in surveillance studies and is recommended for annual monitoring per GeneReviews management guidelines.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"yearly assessment for complications such as hearing loss, hepatic or renal dysfunction, and hypertension."

Identifies hypertension among the recognized late complications of CS warranting yearly surveillance per management guidelines.

Digestive 1

Gastroesophageal Reflux FREQUENT Gastroesophageal reflux (HP:0002020)

Gastroesophageal reflux is reported in approximately 53% of CS patients (CoSyNH cohort) and contributes to feeding difficulties and aspiration risk.

Show evidence (2 references)

PMID:20301516 SUPPORT Human Clinical

"treatment of cataracts and other ophthalmologic complications, hearing loss, hypertension, and gastroesophageal reflux as in the general population"

Lists gastroesophageal reflux as a recognized complication requiring standard management in CS care guidelines.

ORPHA:191 SUPPORT

"HP:0002020 | Gastroesophageal reflux | Frequent (79-30%)"

Orphadata classifies gastroesophageal reflux as frequent (79-30%) in Cockayne syndrome.

Eye 4

Pigmentary Retinopathy VERY_FREQUENT Pigmentary retinopathy (HP:0000580)

Progressive pigmentary retinopathy is a common ophthalmologic feature resulting from retinal photoreceptor degeneration with combined cone and rod system dysfunction. Peripheral retinal vasculopathy and ellipsoid zone abnormalities have also been reported as novel fundus features.

Show evidence (3 references)

PMID:30820731 SUPPORT Human Clinical

"Diffuse pigmentary retinopathy with macular atrophy was found in ultra-wide-field retinography and autofluorescence."

Documents diffuse pigmentary retinopathy with macular involvement in genetically confirmed adult CS patients, supporting the retinopathy phenotype.

PMID:30820731 SUPPORT Human Clinical

"Pigmentary retinopathy in CS could translate a wide dysfunction of the retina with major affection of external retinal layers of both cone and rod cells."

Identifies combined cone and rod system dysfunction underlying pigmentary retinopathy and progressive vision loss in CS.

ORPHA:191 SUPPORT

"HP:0000580 | Pigmentary retinopathy | Very frequent (99-80%)"

Orphadata classifies pigmentary retinopathy as very frequent (99-80%) in Cockayne syndrome.

Optic Atrophy OCCASIONAL Optic atrophy (HP:0000648)

Optic atrophy develops due to degeneration of optic nerve fibers in the context of progressive neurodegeneration.

Show evidence (1 reference)

ORPHA:191 SUPPORT

"HP:0000648 | Optic atrophy | Occasional (29-5%)"

Orphadata classifies optic atrophy as occasional (29-5%) in Cockayne syndrome.

Cataracts FREQUENT Cataract (HP:0000518)

Cataracts occur in approximately 46% of CS patients (CoSyNH cohort) and may be congenital, particularly in the severe type II form. Cataracts diagnosed before age 3 are the strongest negative prognostic indicator, with 5-year survival reduced from ~95% to ~60%.

Show evidence (3 references)

PMID:20301516 SUPPORT Human Clinical

"Congenital cataracts or other structural anomalies of the eye may be present."

Identifies congenital cataracts as a recognized ophthalmologic feature of CS type II in the GeneReviews summary.

PMID:26204423 SUPPORT Human Clinical

"We confirm that the most valuable prognostic factor in CS is the presence of early cataracts."

The CoSyNH cohort (n=102) reported cataracts in approximately 46% of participants and identified early cataracts (before age 3) as the strongest negative prognostic indicator, supporting a frequent and clinically important phenotype.

ORPHA:191 SUPPORT

"HP:0000518 | Cataract | Frequent (79-30%)"

Orphadata classifies cataracts as frequent (79-30%) in Cockayne syndrome.

Deeply Set Eyes FREQUENT Deeply set eye (HP:0000490)

Deep-set, sunken eyes (enophthalmos) are a characteristic feature of the CS facial gestalt, partly due to loss of subcutaneous fat. Enophthalmos is a discriminant feature in the validated Spitz et al. CS diagnostic score (10-item; 95.7% sensitivity, 86.4% specificity).

Show evidence (2 references)

PMID:33536051 SUPPORT Human Clinical

"Short stature, enophtalmos, hearing loss, cataracts, cutaneous photosensitivity, frequent dental caries, enamel hypoplasia, morphological abnormalities of the teeth, areflexia and spasticity were included in the clinical diagnostic score as being the most statistically relevant criteria."

Validates enophthalmos (deeply set eyes) as one of the ten most statistically discriminant features of CS in a 69-patient diagnostic score derivation cohort.

ORPHA:191 SUPPORT

"HP:0000490 | Deeply set eye | Frequent (79-30%)"

Orphadata classifies deeply set eyes as frequent (79-30%) in Cockayne syndrome.

Head and Neck 6

Microcephaly VERY_FREQUENT Microcephaly (HP:0000252)

Show evidence (1 reference)

PMID:39179905 SUPPORT In Vitro

"Cockayne Syndrome B (CSB) is a hereditary multiorgan syndrome which-through largely unknown mechanisms-can affect the brain where it clinically presents with microcephaly, intellectual disability and demyelination."

Explicitly names microcephaly as a clinical presentation of CSB.

Carious Teeth FREQUENT Carious teeth (HP:0000670)

Frequent dental caries is part of the validated 10-item CS diagnostic score, with multifactorial etiology including enamel hypoplasia, soft cariogenic diet, and reduced salivary flow.

Show evidence (3 references)

PMID:23311583 SUPPORT Human Clinical

"Dental caries was associated with enamel defects, a high sugar/carbohydrate soft food diet, poor oral hygiene and dry mouth."

Identifies frequent dental caries as a recognized oro-dental feature of CS, multifactorial in origin (enamel defects, diet, hygiene, and dry mouth).

PMID:33536051 SUPPORT Human Clinical

Validates frequent dental caries as one of the ten most discriminant features in the Spitz et al. validated CS diagnostic score.

ORPHA:191 SUPPORT

"HP:0000670 | Carious teeth | Frequent (79-30%)"

Orphadata classifies carious teeth as frequent (79-30%) in Cockayne syndrome.

Enamel Hypoplasia FREQUENT Enamel hypoplasia (HP:0006297)

Enamel hypoplasia is part of the validated CS diagnostic score and contributes to caries susceptibility.

Show evidence (3 references)

PMID:23311583 SUPPORT Human Clinical

"Various oro-facial and dental anomalies were found: retrognathia; micrognathia; high- arched narrow palate; tooth crowding; hypodontia (missing permanent lateral incisor, second premolars or molars), screwdriver shaped incisors, microdontia, radiculomegaly, and enamel hypoplasia."

Documents enamel hypoplasia as one of multiple recognized oro-dental anomalies in a 17-patient CS cohort.

PMID:33536051 SUPPORT Human Clinical

Validates enamel hypoplasia among the ten most discriminant diagnostic features of CS.

ORPHA:191 SUPPORT

"HP:0006297 | Enamel hypoplasia | Frequent (79-30%)"

Orphadata classifies enamel hypoplasia as frequent (79-30%) in Cockayne syndrome.

Hypodontia OCCASIONAL Hypodontia (HP:0000668)

Hypodontia, including newly reported agenesis of second permanent molars, is part of the cranio-oro-facial phenotype of CS.

Show evidence (1 reference)

PMID:23311583 SUPPORT Human Clinical

"hypodontia (missing permanent lateral incisor, second premolars or molars)"

Documents hypodontia (notably missing lateral incisors, second premolars, and molars including agenesis of second permanent molars) as part of the CS oro-dental phenotype.

Microdontia OCCASIONAL Microdontia (HP:0000691)

Microdontia and atypical tooth morphology (e.g., screwdriver-shaped incisors) are part of the CS oro-dental gestalt.

Show evidence (1 reference)

PMID:23311583 SUPPORT Human Clinical

"screwdriver shaped incisors, microdontia, radiculomegaly, and enamel hypoplasia."

Identifies microdontia among the dental morphology anomalies in CS.

Micrognathia FREQUENT Micrognathia (HP:0000347)

Micrognathia and retrognathia, with cephalometric mid-face hypoplasia, are part of the CS facial gestalt.

Show evidence (1 reference)

PMID:23311583 SUPPORT Human Clinical

"Various oro-facial and dental anomalies were found: retrognathia; micrognathia; high- arched narrow palate; tooth crowding"

Confirms micrognathia and retrognathia as part of the CS cranio-oro-facial phenotype, contributing to mid-face hypoplasia.

Integument 2

Cutaneous Photosensitivity FREQUENT Cutaneous photosensitivity (HP:0000992)

Extreme UV sensitivity causing severe sunburns with minimal exposure is a hallmark of CS, directly reflecting the TC-NER defect. Unlike xeroderma pigmentosum, CS patients are not predisposed to skin cancers.

Show evidence (3 references)

PMID:30988227 SUPPORT Human Clinical

"The clinical features of CS include photosensitivity, a characteristic senile face, significant developmental abnormalities, such as short stature, underweight, and microcephaly, progressive cachexia, severe visual impairment, and sensorineural deafness."

Explicitly lists photosensitivity as a core clinical feature of Cockayne syndrome.

PMID:30988227 SUPPORT Human Clinical

"Unlike XP, in CS, skin cancer is not known to occur in areas of skin exposed to sunlight."

Confirms that despite photosensitivity, CS patients are not predisposed to skin cancers, distinguishing CS from xeroderma pigmentosum.

ORPHA:191 SUPPORT

"HP:0000992 | Cutaneous photosensitivity | Frequent (79-30%)"

Orphadata classifies cutaneous photosensitivity as frequent (79-30%) in Cockayne syndrome.

Progeroid Facial Appearance FREQUENT Progeroid facial appearance (HP:0005328)

Show evidence (1 reference)

PMID:30988227 SUPPORT Human Clinical

Explicitly names "a characteristic senile face" as a clinical feature of CS, directly supporting the progeroid facial appearance phenotype.

Musculoskeletal 5

Spasticity VERY_FREQUENT Spasticity (HP:0001257)

Show evidence (1 reference)

PMID:38674442 SUPPORT Human Clinical

"Various degrees of ataxia and spasticity were cardinal neurologic features, with variably combined systemic characteristics."

Supports spasticity as a common neurologic manifestation in CS.

Muscle Weakness FREQUENT Muscle weakness (HP:0001324)

Muscle weakness is the most common phenotype in the CoSyNH natural history cohort, reported in approximately 78% of patients (80/102), contributing to progressive loss of motor function and ambulation in late-stage disease.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"physical therapy to prevent contractures"

Recommended use of physical therapy to prevent contractures in CS care guidelines reflects underlying progressive motor weakness and functional impairment.

Intracranial Calcification FREQUENT Intracranial calcification (HP:0430048)

Basal ganglia calcification (predominantly in the putamen) is a hallmark neuroimaging finding in Cockayne syndrome, occurring in ~55% of imaged patients in the CoSyNH cohort. Calcifications result from chronic tissue injury and mineral deposition and are part of the validated clinical-radiologic diagnostic score.

Show evidence (2 references)

PMID:20522568 SUPPORT Human Clinical

"Hypomyelination, calcifications, and brain atrophy were the main imaging features. Calcifications were typically found in the putamen and less often in the cortex and dentate nuclei."

Confirms intracranial calcification (with putaminal predominance) as a hallmark neuroimaging feature in a genetically confirmed CS cohort.

PMID:27643390 SUPPORT Human Clinical

"Cockayne syndrome (CS) is a rare disorder characterized by severe brain atrophy, white matter (WM) hypomyelination and basal ganglia calcifications."

Reinforces basal ganglia calcifications among the cardinal imaging features of CS in a quantitative MRI cohort study.

Kyphosis FREQUENT Kyphosis (HP:0002808)

Kyphosis develops as part of the spinal contracture profile of CS, particularly in severe early-onset forms.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints."

Confirms kyphosis as a recognized spinal deformity in CS, especially in the severe type II form.

Scoliosis FREQUENT Scoliosis (HP:0002650)

Scoliosis is reported in approximately 48% of CS patients (CoSyNH cohort) and contributes to progressive musculoskeletal disability.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints."

Confirms scoliosis as a recognized spinal deformity in CS, especially in the severe type II form.

Nervous System 12

Intellectual Disability OCCASIONAL Intellectual disability (HP:0001249)

Show evidence (2 references)

PMID:39179905 SUPPORT In Vitro

Identifies intellectual disability as a core clinical manifestation in CSB.

ORPHA:191 SUPPORT

"HP:0001249 | Intellectual disability | Occasional (29-5%)"

Orphadata classifies intellectual disability as occasional (29-5%) in Cockayne syndrome. The higher-frequency cognitive phenotype is better captured by HP:0001268 (Mental deterioration), which ORPHA classifies as Very frequent (99-80%).

CNS Demyelination VERY_FREQUENT CNS demyelination (HP:0007305)

Show evidence (1 reference)

PMID:39179905 SUPPORT In Vitro

Supports demyelination as a defining neurologic phenotype.

Progressive Peripheral Demyelination FREQUENT Peripheral demyelination (HP:0011096)

Show evidence (1 reference)

PMID:36190439 SUPPORT Human Clinical

"Cockayne syndrome has classically been linked to demyelinating polyneuropathies, whereas xeroderma pigmentosum has long been associated with axonal polyneuropathies."

Supports the peripheral demyelinating neuropathy phenotype in CS.

Ataxia FREQUENT Ataxia (HP:0001251)

Show evidence (2 references)

PMID:38674442 SUPPORT Human Clinical

"Various degrees of ataxia and spasticity were cardinal neurologic features, with variably combined systemic characteristics."

Identifies ataxia as a cardinal neurologic feature in ERCC6-related CS.

ORPHA:191 SUPPORT

"HP:0001251 | Ataxia | Frequent (79-30%)"

Orphadata classifies ataxia as frequent (79-30%) in Cockayne syndrome.

Areflexia FREQUENT Areflexia (HP:0001284)

Areflexia is part of the validated 10-item Spitz CS clinical diagnostic score, reflecting peripheral nerve involvement and demyelinating polyneuropathy.

Show evidence (1 reference)

PMID:33536051 SUPPORT Human Clinical

Validates areflexia as one of the ten most statistically discriminant features of CS in the validated Spitz et al. CS diagnostic score (95.7% sensitivity, 86.4% specificity).

Cerebellar Atrophy VERY_FREQUENT Cerebellar atrophy (HP:0001272)

Show evidence (2 references)

ORPHA:191 SUPPORT

"HP:0001272 | Cerebellar atrophy | Very frequent (99-80%)"

Orphadata classifies cerebellar atrophy as very frequent (99-80%) in Cockayne syndrome.

PMID:27643390 SUPPORT Human Clinical

"Total brain volume in CS was reduced by 57%, predominantly in the infratentorial area"

Quantifies severe infratentorial volume reduction supporting cerebellar atrophy as a predominant imaging feature.

Mental Deterioration VERY_FREQUENT Mental deterioration (HP:0001268)

Show evidence (2 references)

ORPHA:191 SUPPORT

"HP:0001268 | Mental deterioration | Very frequent (99-80%)"

Orphadata classifies mental deterioration as very frequent (99-80%) in Cockayne syndrome.

PMID:38808024 SUPPORT Human Clinical

"Among 18 individuals who met inclusion criteria, all but one (94.4%) experienced at least one symptom of neurocognitive/neuropsychiatric decline, with most individuals experiencing at least half of those symptoms."

Confirms near-universal neurocognitive decline in adult CS survivors.

Atypical Behavior VERY_FREQUENT Atypical behavior (HP:0000708)

Show evidence (2 references)

ORPHA:191 SUPPORT

"HP:0000708 | Atypical behavior | Very frequent (99-80%)"

Orphadata classifies atypical behavior as very frequent (99-80%) in Cockayne syndrome.

PMID:38808024 SUPPORT Human Clinical

Near-universal neuropsychiatric symptoms in adult CS survivors support behavioral abnormalities as a very frequent feature.

Tremor FREQUENT Tremor (HP:0001337)

Tremor is reported in approximately 65% of CS patients in the CoSyNH pediatric cohort and in 83.3% of adult survivors, often combined with cerebellar dysarthria and ataxia.

Show evidence (2 references)

PMID:38808024 SUPPORT Human Clinical

"Most participants experienced tremors and peripheral neuropathy, with a few experiencing seizures and strokes."

Documents tremor as a near-universal late-stage neurologic manifestation in adult CS survivors (15/18, 83.3%).

PMID:20301516 SUPPORT Human Clinical

"medications for tremor and spasticity as needed"

Indicates tremor as a recognized treatable manifestation in standard CS care guidelines.

Seizures FREQUENT Seizure (HP:0001250)

Seizures occur in approximately 23% of CS patients (CoSyNH cohort) and in 28% of adult survivors, often in the context of progressive cortical injury and cerebral atrophy. Orphadata classifies seizures as frequent (79-30%).

Show evidence (2 references)

PMID:38808024 SUPPORT Human Clinical

"Most participants experienced tremors and peripheral neuropathy, with a few experiencing seizures and strokes."

Identifies seizures as a less frequent but recognized complication in adult CS survivors (5/18, 27.8%).

ORPHA:191 SUPPORT

"HP:0001250 | Seizure | Frequent (79-30%)"

Orphadata classifies seizures as frequent (79-30%) in Cockayne syndrome, supporting upgrade from OCCASIONAL.

Cerebral Atrophy FREQUENT Cerebral atrophy (HP:0002059)

Progressive global cerebral atrophy is a near-universal MRI finding, with prominent cerebellar and corpus callosum involvement.

Show evidence (3 references)

PMID:27643390 SUPPORT Human Clinical

"Total brain volume in CS was reduced by 57%, predominantly in the infratentorial area"

Quantifies severe brain atrophy (57% volume reduction with infratentorial predominance) as a hallmark imaging feature.

PMID:38808024 SUPPORT Human Clinical

"85.7% had generalized cerebral atrophy on MRI while 78.6% had white matter changes."

Confirms generalized cerebral atrophy on MRI in 85.7% of adult CS survivors with available imaging.

ORPHA:191 SUPPORT

"HP:0002059 | Cerebral atrophy | Frequent (79-30%)"

Orphadata classifies cerebral atrophy as frequent (79-30%) in Cockayne syndrome.

Cerebral Hypomyelination FREQUENT Cerebral hypomyelination (HP:0006808)

Diffuse cerebral white matter hypomyelination (leukodystrophy) is part of the validated Spitz CS clinical-radiological diagnostic score and helps distinguish CS from other childhood leukoencephalopathies.

Show evidence (2 references)

PMID:20522568 SUPPORT Human Clinical

"Hypomyelination, calcifications, and brain atrophy were the main imaging features."

Identifies hypomyelination as one of the three principal neuroimaging features of CS in a genetically and biochemically confirmed cohort.

PMID:27643390 SUPPORT Human Clinical

"Mean ADC values corresponded to a hypomyelinating disorder."

DTI-based quantitative confirmation that CS white matter abnormalities correspond to a hypomyelinating disorder pattern.

Growth 2

Short Stature (Cachectic Dwarfism) VERY_FREQUENT Short stature (HP:0004322)

Show evidence (1 reference)

PMID:39473441 SUPPORT Human Clinical

"BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal recessive disorder characterized by cachectic dwarfism, nervous system abnormalities, and premature aging."

Supports growth impairment with cachectic dwarfism/short stature as a clinical hallmark.

Failure to Thrive VERY_FREQUENT Failure to thrive (HP:0001508)

Severe growth and weight deficiency is a cardinal feature. Children show progressive weight and length decline below the 5th percentile.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile."

Confirms severe postnatal growth and weight deficiency below the fifth percentile as a defining clinical feature of fully manifest CS.

Other 3

Sensorineural Hearing Impairment VERY_FREQUENT Progressive sensorineural hearing impairment (HP:0000408)

Progressive sensorineural hearing loss is a well-established feature of CS, owing to degeneration of cochlear nerve fibers. Hearing loss is reported in approximately 63% of patients in the CoSyNH cohort. Temporal bone histopathology shows stria vascularis atrophy and spiral ganglion neuronal loss.

Show evidence (3 references)

PMID:29447894 SUPPORT Human Clinical

"Cockayne Syndrome (CS) is a rare, autosomal recessive disorder characterized by a spectrum of phenotypic abnormalities, including progressive sensorineural hearing loss (SNHL) that involves both peripheral and central components."

Identifies progressive sensorineural hearing loss as an established feature of CS, with both peripheral cochlear and central auditory components.

PMID:29649050 SUPPORT Human Clinical

"Severe atrophy of the spiral ligament and atrophy of stria vascularis and spiral prominence was present."

Provides direct histopathologic evidence of cochlear pathology in CS, including severe stria vascularis and spiral ligament atrophy underlying the sensorineural hearing impairment.

ORPHA:191 SUPPORT

"HP:0000408 | Progressive sensorineural hearing impairment | Very frequent (99-80%)"

Orphadata classifies progressive sensorineural hearing impairment as very frequent (99-80%) in Cockayne syndrome.

Cachexia VERY_FREQUENT Cachexia (HP:0004326)

Show evidence (2 references)

ORPHA:191 SUPPORT

"HP:0004326 | Cachexia | Very frequent (99-80%)"

Orphadata classifies cachexia as very frequent (99-80%) in Cockayne syndrome.

PMID:39473441 SUPPORT Human Clinical

"BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal recessive disorder characterized by cachectic dwarfism, nervous system abnormalities, and premature aging."

Identifies cachectic dwarfism as a defining clinical characteristic of CS.

Multiple Joint Contractures FREQUENT Multiple joint contractures (HP:0002828)

Joint contractures are reported in approximately 63% of CS patients (CoSyNH cohort), reflecting both early postnatal involvement (especially in CS type II/COFS) and later progressive limitation of joint mobility.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints."

Identifies early postnatal joint contractures as a recognized feature of CS, especially in the severe type II form.

🧬

Genetic Associations

ERCC6 (Pathogenic Variants)

Show evidence (1 reference)

PMID:39473441 SUPPORT Human Clinical

"Mutations in the ERCC6 and ERCC8 genes are the predominant causes of Cockayne syndrome, with ERCC6 gene mutations present in approximately 75% of cases."

Supports ERCC6 as the predominant molecular contributor in CS.

ERCC8 (Pathogenic Variants)

Show evidence (1 reference)

PMID:39473441 SUPPORT Human Clinical

"Mutations in the ERCC6 and ERCC8 genes are the predominant causes of Cockayne syndrome, with ERCC6 gene mutations present in approximately 75% of cases."

Supports ERCC8 as a principal causative gene in Cockayne syndrome.

💊

Treatments

Nicotinamide Supplementation

Action: nicotinamide supplementation Ontology label: dietary intervention MAXO:0000088

Nicotinamide has been explored experimentally in CS cellular models to reduce inflammatory and oxidative stress abnormalities, enhance autophagy, and restore mitochondrial DNA polymerase gamma (POLG1) levels. Clinical benefit remains to be established.

Show evidence (2 references)

PMID:39611850 SUPPORT In Vitro

"The supplementation with nicotinamide adjusted these abnormalities by enhancing autophagy and decreasing inflammation."

Supports nicotinamide modulation of oxidative stress and autophagy in patient-derived cellular systems.

PMID:39611850 SUPPORT In Vitro

"CSA/CSB-dependent depletion of the mitochondrial DNA polymerase-γ catalytic subunit (POLG1) was restored following nicotinamide supplementation in CS-affected individuals' fibroblasts."

Demonstrates nicotinamide can restore POLG1 levels in CS cells, suggesting potential mitochondrial benefit.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Genetic counseling is important for recurrence-risk assessment and reproductive planning in affected families, including discussion of PGT-M options.

Show evidence (1 reference)

PMID:39473441 SUPPORT Human Clinical

"The findings of this study broaden the variant spectrum of ERCC6 and will contribute to the molecular diagnosis and genetic counseling of CS."

Directly supports genetic counseling as a core component of clinical management.

Supportive Care

Action: supportive care MAXO:0000950

Multidisciplinary supportive management including strict UV avoidance, nutritional support, hearing aids, ophthalmologic monitoring, and management of contractures through rehabilitation. No curative therapy exists. Yearly surveillance is recommended for hearing loss, hepatic and renal dysfunction, and hypertension.

Show evidence (2 references)

PMID:20301516 SUPPORT Human Clinical

"Treatment of manifestations: Feeding gastrostomy tube placement as needed; individualized educational programs for developmental delay; medications for tremor and spasticity as needed; physical therapy to prevent contractures"

Documents the multimodal supportive care approach recommended in the GeneReviews CS management summary, including feeding support, rehabilitation, and symptom-targeted pharmacotherapy.

PMID:26204423 SUPPORT Human Clinical

"Using this evidence, we have created simple guidelines for the care of individuals with CS."

Establishes the CoSyNH multidisciplinary care guidelines as the evidence base for supportive management in CS.

Photoprotection and Sunlight Avoidance

Action: sunlight avoidance MAXO:0000055

Strict avoidance of excessive sun exposure, with consistent use of broad-spectrum sunscreens and protective sunglasses for lens and retinal protection. UV avoidance is critical given the underlying TC-NER defect and severe photosensitivity.

Show evidence (2 references)

PMID:20301516 SUPPORT Human Clinical

"use of sunscreens and limitation of sun exposure for cutaneous photosensitivity."

Recommends sunscreens and sun exposure limitation as the cornerstone intervention for cutaneous photosensitivity in CS management guidelines.

PMID:20301516 SUPPORT Human Clinical

"use of sunglasses for lens/retina protection"

Supports use of sunglasses for ophthalmologic photoprotection in CS.

Cochlear Implantation

Action: cochlear device implantation MAXO:0009025

Cochlear implantation can be effective for managing progressive sensorineural hearing loss in CS pediatric patients, with reported improvements in speech perception scores and quality of life. Best outcomes are seen in patients with post-lingual hearing loss or better cognitive function.

Show evidence (2 references)

PMID:29447894 SUPPORT Human Clinical

"Subjective benefits were noted early after activation in both patients, and speech perception scores improved over time as well, varying from 42 to 70% (versus 0-12% previously)."

Documents quantitative improvements in speech perception following cochlear implantation in pediatric CS patients with progressive sensorineural hearing loss.

PMID:38803843 SUPPORT Human Clinical

"The study underscores the benefits of cochlear implantation in CS patients, especially in patients who are post-lingual or with better cognitive function."

Confirms cochlear implantation benefit in additional CS type I pediatric cases, identifying post-lingual onset and cognitive function as predictors of better outcome.

Gastrostomy Feeding Support

Action: gastrostomy MAXO:0001346

Placement of a feeding gastrostomy tube to support nutrition and caloric intake, with careful titration to avoid rapid weight gain. This is a key supportive intervention given the cachectic dwarfism, feeding difficulties, and reflux that are characteristic of CS.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"Feeding gastrostomy tube placement as needed"

Identifies feeding gastrostomy tube placement as a recommended nutritional support intervention in CS care guidelines.

Aggressive Dental Care

Action: dental and oral agent therapy MAXO:0000264

Proactive and aggressive preventive dental care is essential to minimize dental caries, given the multifactorial caries susceptibility from enamel hypoplasia, soft cariogenic diet, and reduced salivary flow.

Show evidence (1 reference)

PMID:20301516 SUPPORT Human Clinical

"aggressive dental care to minimize dental caries"

Identifies aggressive dental care as a recommended preventive intervention in CS management guidelines.

{ }

Source YAML

click to show

name: Cockayne Syndrome
creation_date: "2026-03-15T23:04:21Z"
updated_date: "2026-04-28T12:00:00Z"
description: >-
  Cockayne syndrome is an ultra-rare autosomal recessive multisystem DNA repair
  disorder caused primarily by ERCC6 or ERCC8 dysfunction. It is a segmental
  progeroid syndrome with defective transcription-coupled nucleotide excision
  repair (TC-NER), resulting in progressive neurodevelopmental and
  neurodegenerative manifestations, cachectic dwarfism, photosensitivity, and
  premature aging across multiple organ systems.
category: Genetic
parents:
  - DNA Repair Disorder
  - Progeroid Syndrome
  - Neurodevelopmental Disorder
synonyms:
  - Cockayne syndrome
  - Cockayne's syndrome
  - Neill-Dingwall syndrome
disease_term:
  preferred_term: Cockayne syndrome
  term:
    id: MONDO:0016006
    label: Cockayne syndrome
prevalence:
  - population: United States
    percentage: 0.000004
    notes: >-
      Estimated prevalence approximately 1 in 250,000 in the United States.
    evidence:
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "The incidence of CS has been estimated at 1/360,000 births in western Europe"
        explanation: >-
          Provides a published incidence figure (~1 in 360,000 in western
          Europe), of the same order of magnitude as the U.S. estimate listed
          here, supporting Cockayne syndrome as an ultra-rare disorder.
  - population: Western Europe
    percentage: 0.00027
    notes: >-
      Incidence of 2.7 per million livebirths across five western European
      countries (France, Germany, Italy, Netherlands, United Kingdom), based
      on combined data from DNA repair diagnostic centres. In the autochthonic
      population the incidence is 1.8 per million.
    evidence:
      - reference: PMID:18329345
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Incidences in western Europe were for the first time established at
          2.3 per million livebirths for XP, 2.7 per million for CS and 1.2
          per million for TTD.
        explanation: >-
          First systematic incidence estimate for CS in western Europe from
          combined diagnostic centre data across five countries.
      - reference: PMID:18329345
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          incidences were also established for the autochthonic western European
          population at: 0.9 per million for XP, 1.8 per million for CS and
          1.1 per million for TTD.
        explanation: >-
          Provides the incidence in the native Western European population,
          adjusting for the disproportionate representation of immigrant
          populations among diagnosed cases.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "1-9 / 1 000 000 | France | Prevalence at birth | PMID:18329345"
        explanation: >-
          Orphadata epidemiology data confirms European birth prevalence in the
          1-9 per million range, citing the same primary source.
has_subtypes:
  - name: Cockayne syndrome type I
    description: >-
      Classic form with onset in the first 1-2 years of life, progressive
      neurologic and systemic involvement, and death typically in the first or
      second decade.
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Four patients had CS I, three patients CS II, and one patient CS III."
        explanation: >-
          This cohort directly confirms clinical subtype stratification including
          type I.
  - name: Cockayne syndrome type II
    description: >-
      Severe congenital or early-onset form with prenatal or neonatal
      manifestations, minimal neurologic development, and early lethality.
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our work confirms clinical variability also in the ERCC6/CSB type,
          where manifestations may range from severe involvement with prenatal or
          neonatal onset to normal psychomotor development followed by
          progressive ataxia.
        explanation: >-
          Supports severe early-onset disease biology consistent with type II
          presentations.
  - name: Cockayne syndrome type III
    description: >-
      Milder form with relatively later onset, less severe progression, and
      longer survival.
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Four patients had CS I, three patients CS II, and one patient CS III."
        explanation: >-
          Confirms type III within the observed ERCC6-related spectrum.
progression:
  - phase: Variable onset and progression
    notes: >-
      Clinical variability ranges from severe congenital onset (type II) to
      classic childhood onset (type I) with progressive neurologic decline and
      death in the first or second decade, to a milder form (type III) with
      later onset and prolonged survival. Serum neurofilament light chain (sNFL)
      has been proposed as a peripheral biomarker of disease severity (45-270
      pg/mL range in tested patients, above the 99th percentile of reference
      values). The CoSyNH natural history cohort (n=102) reported a mean age at
      death of 8.4 years (range 17 months to 30 years) and identified early
      cataracts as the strongest negative prognostic indicator. A multicenter
      adult cohort showed near-universal late-stage neurocognitive/
      neuropsychiatric decline (94.4%), tremor (83.3%), and peripheral
      neuropathy (72.2%) in CS individuals surviving beyond age 18.
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Our work confirms clinical variability also in the ERCC6/CSB type,
          where manifestations may range from severe involvement with prenatal or
          neonatal onset to normal psychomotor development followed by
          progressive ataxia.
        explanation: >-
          Supports broad onset heterogeneity with progressive neurologic decline.
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We propose, for the first time in CS, sNFL as a useful peripheral
          biomarker, with increased levels compared to currently available
          reference values and with the potential ability to reflect disease
          severity.
        explanation: >-
          Supports sNFL as a biomarker of progressive neurodegeneration in CS.
      - reference: PMID:26204423
        reference_title: "The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We confirm that the most valuable prognostic factor in CS is the
          presence of early cataracts.
        explanation: >-
          Identifies early cataracts as the principal negative prognostic
          indicator from the largest natural history cohort to date (n=102),
          informing surveillance and counseling.
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Among 18 individuals who met inclusion criteria, all but one (94.4%)
          experienced at least one symptom of neurocognitive/neuropsychiatric
          decline, with most individuals experiencing at least half of those
          symptoms.
        explanation: >-
          Supports near-universal late-stage neurocognitive decline as an
          emergent feature in adult CS survivors, broadening the recognized
          progression beyond the pediatric phase.
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          This rare condition encompasses a very wide spectrum of clinical
          severity levels ranging from severe prenatal onset to mild adult-onset
          subtypes.
        explanation: >-
          Reinforces the continuous spectrum of severity from prenatal to
          adult-onset forms, on which the validated CS severity score is built.
pathophysiology:
  - name: Defective Transcription-Coupled Nucleotide Excision Repair
    description: >-
      Pathogenic ERCC6/ERCC8 variants impair transcription-coupled nucleotide
      excision repair (TC-NER), disrupting removal of transcription-blocking DNA
      lesions in actively transcribed genes. TC-NER is initiated by stalling of
      elongating RNA polymerase complexes at damaged sites.
    biological_processes:
      - preferred_term: transcription-coupled nucleotide-excision repair
        term:
          id: GO:0006283
          label: transcription-coupled nucleotide-excision repair
    evidence:
      - reference: PMID:40723898
        reference_title: "Transcription-Coupled Nucleotide Excision Repair: A Faster Solution or the Only Option?"
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          A branch of the nucleotide excision repair (NER) pathway,
          transcription-coupled repair (TCR or TC-NER) specifically operates on
          the template DNA strand of actively transcribed genes.
        explanation: >-
          Defines the core repair pathway mechanistically affected in Cockayne
          syndrome biology.
      - reference: PMID:40332372
        reference_title: "Transcription-Coupled Repair and R-Loop Crosstalk in Genome Stability."
        supports: SUPPORT
        evidence_source: OTHER
        snippet: >-
          TCR, a specialized sub-pathway of nucleotide excision repair, rapidly
          removes transcription-blocking lesions from the transcribed strand of
          active genes, thereby safeguarding transcription fidelity and cellular
          homeostasis.
        explanation: >-
          Reinforces TC-NER as the critical pathway disrupted in CS, with
          consequences for transcription fidelity.
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          (1) Background: Cockayne syndrome (CS) is an ultra-rare multisystem
          disorder, classically subdivided into three forms and characterized by
          a clinical spectrum without a clear genotype-phenotype correlation for
          both the two causative genes ERCC6 (CS type B) and ERCC8 (CS type A).
        explanation: >-
          Provides direct human clinical-genetic evidence that ERCC6 and ERCC8
          are the main causal genes.
    downstream:
      - target: Impaired Neural Progenitor Migration
        description: >-
          CSB-deficient iPSC-derived neural models exhibit impaired neural
          progenitor migration via defective autophagy, linking the upstream
          TC-NER defect to clinical microcephaly.
        causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
        intermediate_mechanisms:
          - defective autophagy
      - target: Impaired Oligodendrocyte Maturation
        description: >-
          CSB deficiency impairs oligodendrocyte maturation in iPSC-derived
          neural systems, providing a downstream cellular consequence of the
          underlying TC-NER defect that explains CNS demyelination.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Disturbed Developmental GABA Switch
        description: >-
          CSB deficiency in iPSC-derived neural models produces abnormal GABA
          neurotransmitter levels suggestive of a disturbed developmental GABA
          switch downstream of the underlying TC-NER defect.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: NRF2 Pathway Repression
        description: >-
          CS fibroblasts show repression of the NRF2 oxidative-stress response
          pathway, identifying redox dysregulation as a downstream consequence
          of impaired TC-NER and DNA-repair-coupled transcription.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Arachidonic Acid Metabolism Activation
        description: >-
          CS fibroblasts show inflammatory activation of arachidonic acid
          metabolism downstream of impaired DNA-repair-coupled transcription.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Mitochondrial DNA Maintenance Deficiency
        description: >-
          Loss of CSA/CSB function leads to depletion of mitochondrial DNA
          polymerase gamma (POLG1), placing mitochondrial DNA maintenance
          deficiency downstream of the upstream TC-NER/transcription defect.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Epigenomic Acceleration of Aging
        description: >-
          CS fibroblasts develop a progeroid-specific DNA methylation signature
          that is absent in UV-sensitive syndrome (which shares the NER defect
          but lacks progeria), implicating CSA/CSB-dependent transcription
          functions as the upstream driver of accelerated epigenomic aging.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
      - target: Peripheral Demyelinating Neuropathy Susceptibility
        description: >-
          The CS TC-NER defect renders long-lived myelinating Schwann cells
          vulnerable to unrepaired transcription-blocking DNA lesions,
          producing the characteristic demyelinating polyneuropathy phenotype.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Impaired Neural Progenitor Migration
    description: >-
      CSB deficiency causes impaired neural progenitor cell migration due to
      defective autophagy, providing a mechanistic explanation for the
      microcephaly observed in Cockayne syndrome.
    cell_types:
      - preferred_term: neural progenitor cell
        term:
          id: CL:0011020
          label: neural progenitor cell
    biological_processes:
      - preferred_term: autophagy
        term:
          id: GO:0006914
          label: autophagy
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          In our models, CSB deficiency is associated with (i) impaired cellular
          migration due to defective autophagy as an explanation for clinical
          microcephaly
        explanation: >-
          Directly links impaired migration via defective autophagy to
          microcephaly in CSB.
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Of note, the impaired migration and oligodendrocyte maturation could
          both be partially rescued by pharmacological HDAC inhibition.
        explanation: >-
          Demonstrates pharmacological rescue potential for the migration
          defect, suggesting a targetable pathway.
  - name: Disturbed Developmental GABA Switch
    description: >-
      CSB-deficient neurons show abnormal GABA neurotransmitter levels,
      suggestive of a disturbed developmental GABA switch that impairs brain
      circuit formation and causes intellectual disability.
    cell_types:
      - preferred_term: neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: gamma-aminobutyric acid signaling pathway
        term:
          id: GO:0007214
          label: gamma-aminobutyric acid signaling pathway
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          altered neuronal network functionality and neurotransmitter GABA
          levels, which is suggestive of a disturbed GABA switch that likely
          impairs brain circuit formation and ultimately causes intellectual
          disability
        explanation: >-
          Identifies disturbed GABA switch as a mechanism underlying
          intellectual disability in CSB.
    downstream:
      - target: Impaired Neuronal Network Formation
        description: >-
          The disturbed developmental GABA switch impairs brain circuit
          formation in CSB-deficient iPSC-derived neural models, directly
          producing altered neuronal network functionality.
        causal_link_type: DIRECT
  - name: Impaired Neuronal Network Formation
    description: >-
      CSB-deficient neurons show altered network functionality in
      iPSC-derived 3D neural models, indicating impaired neuronal network
      formation.
    cell_types:
      - preferred_term: neuron
        term:
          id: CL:0000540
          label: neuron
    biological_processes:
      - preferred_term: neurogenesis
        term:
          id: GO:0022008
          label: neurogenesis
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          altered neuronal network functionality and neurotransmitter GABA
          levels, which is suggestive of a disturbed GABA switch that likely
          impairs brain circuit formation and ultimately causes intellectual
          disability
        explanation: >-
          Demonstrates altered neuronal network functionality in CSB-deficient
          neural models.
  - name: Impaired Oligodendrocyte Maturation
    description: >-
      CSB deficiency impairs oligodendrocyte maturation in human iPSC-derived
      3D neural models, providing a mechanistic basis for the demyelination
      observed in Cockayne syndrome.
    cell_types:
      - preferred_term: oligodendrocyte precursor cell
        term:
          id: CL:0002453
          label: oligodendrocyte precursor cell
    biological_processes:
      - preferred_term: oligodendrocyte differentiation
        term:
          id: GO:0048709
          label: oligodendrocyte differentiation
      - preferred_term: myelination
        term:
          id: GO:0042552
          label: myelination
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          (iii) impaired oligodendrocyte maturation as a possible cause of the
          demyelination observed in children with CSB.
        explanation: >-
          Directly links oligodendrocyte maturation failure to clinical
          demyelination.
  - name: NRF2 Pathway Repression
    description: >-
      Cockayne syndrome fibroblasts show repression of the NRF2 oxidative stress
      response pathway, contributing to dysregulated redox homeostasis. This
      abnormality is partially reversible with nicotinamide supplementation.
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: response to oxidative stress
        term:
          id: GO:0006979
          label: response to oxidative stress
    evidence:
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Gene expression analysis revealed alterations in two main pathways.
          This involves the activation of arachidonic acid metabolism and the
          repression of the NRF2 pathway in affected individuals with CS.
        explanation: >-
          Identifies NRF2 pathway repression as a key oxidative stress defect in
          CS fibroblasts.
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The supplementation with nicotinamide adjusted these abnormalities by
          enhancing autophagy and decreasing inflammation.
        explanation: >-
          Demonstrates nicotinamide can partially rescue the NRF2-related
          abnormalities.
    downstream:
      - target: Accelerated Cellular Senescence
        description: >-
          NRF2 pathway repression compromises antioxidant defenses and links
          oxidative stress to accelerated cellular senescence in CS fibroblasts.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Arachidonic Acid Metabolism Activation
    description: >-
      Cockayne syndrome fibroblasts show activation of arachidonic acid
      metabolism, contributing to inflammatory dysregulation. This abnormality
      is partially reversible with nicotinamide supplementation.
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: arachidonate metabolic process
        term:
          id: GO:0019369
          label: arachidonate metabolic process
    evidence:
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Gene expression analysis revealed alterations in two main pathways.
          This involves the activation of arachidonic acid metabolism and the
          repression of the NRF2 pathway in affected individuals with CS.
        explanation: >-
          Identifies arachidonic acid metabolism activation as a key
          inflammatory pathway perturbation in CS fibroblasts.
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The supplementation with nicotinamide adjusted these abnormalities by
          enhancing autophagy and decreasing inflammation.
        explanation: >-
          Demonstrates nicotinamide can partially rescue the inflammatory
          abnormalities including arachidonic acid pathway activation.
    downstream:
      - target: Accelerated Cellular Senescence
        description: >-
          Arachidonic acid metabolism activation drives chronic inflammatory
          signaling that contributes to accelerated cellular senescence in CS
          fibroblasts.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Mitochondrial DNA Maintenance Deficiency
    description: >-
      CS proteins participate in mitochondrial homeostasis. CSA/CSB deficiency
      leads to depletion of mitochondrial DNA polymerase gamma (POLG1), which
      can be restored by nicotinamide supplementation, linking nuclear DNA repair
      defects to mitochondrial dysfunction.
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: mitochondrial DNA replication
        term:
          id: GO:0006264
          label: mitochondrial DNA replication
    evidence:
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          CSA/CSB-dependent depletion of the mitochondrial DNA polymerase-γ
          catalytic subunit (POLG1) was restored following nicotinamide
          supplementation in CS-affected individuals' fibroblasts.
        explanation: >-
          Demonstrates that CS proteins are required for mitochondrial DNA
          maintenance via POLG1, providing a mechanistic link between nuclear
          DNA repair defects and mitochondrial dysfunction.
    downstream:
      - target: Mitochondrial Dysfunction with Impaired Mitophagy
        description: >-
          POLG1 depletion compromises mitochondrial DNA maintenance and
          contributes to the broader mitochondrial dysfunction and impaired
          mitophagy phenotype seen in CS cells and tissues.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Mitochondrial Dysfunction with Impaired Mitophagy
    description: >-
      Cross-species transcriptomic and biochemical studies demonstrate that
      Cockayne syndrome involves mitochondrial dysfunction and compromised
      mitophagy/autophagy, contributing to accelerated cellular aging.
      Restoration of NAD+ levels through precursor supplementation rescues
      mitochondrial dysfunction in CS cellular and nematode models, identifying
      NAD+ signaling as a convergent target connecting DNA damage accumulation
      with mitochondrial failure.
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: mitophagy
        term:
          id: GO:0000423
          label: mitophagy
      - preferred_term: NAD+ biosynthetic process
        term:
          id: GO:0009435
          label: NAD+ biosynthetic process
    evidence:
      - reference: PMID:33166073
        reference_title: "Cockayne syndrome proteins CSA and CSB maintain mitochondrial homeostasis through NAD(+) signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Our cross-species transcriptomic analysis in CS postmortem brain
          tissue, CS mouse, and nematode models shows that mitochondrial
          dysfunction is indeed a common feature in CS.
        explanation: >-
          Establishes mitochondrial dysfunction as a conserved pathogenic
          feature of CS across species and tissue contexts.
      - reference: PMID:33166073
        reference_title: "Cockayne syndrome proteins CSA and CSB maintain mitochondrial homeostasis through NAD(+) signaling."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          In primary cells depleted for CSA or CSB, this dysfunction can be
          corrected with supplementation of NAD+ precursors.
        explanation: >-
          Demonstrates rescue of mitochondrial defects via NAD+ precursor
          supplementation, supporting NAD+ signaling as a key mechanistic and
          therapeutic node.
    downstream:
      - target: Accelerated Cellular Senescence
        description: >-
          Mitochondrial dysfunction and impaired mitophagy drive accumulation
          of damaged mitochondria, oxidative stress, and energetic failure
          that converge on accelerated cellular senescence in CS.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Epigenomic Acceleration of Aging
    description: >-
      Genome-wide DNA methylation profiling distinguishes Cockayne syndrome
      fibroblasts from those of UV-sensitive syndrome (which lacks the
      progeroid phenotype) and identifies a CS-specific epigenomic signature
      associated with accelerated biological age. The CS-specific differentially
      methylated genes are enriched in developmental transcription factors and
      synaptic neurodevelopmental programs.
    cell_types:
      - preferred_term: fibroblast
        term:
          id: CL:0000057
          label: fibroblast
    biological_processes:
      - preferred_term: epigenetic regulation of gene expression
        term:
          id: GO:0040029
          label: epigenetic regulation of gene expression
    evidence:
      - reference: PMID:37688320
        reference_title: "Epigenomic signature of accelerated ageing in progeroid Cockayne syndrome."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Differential analysis highlighted a CS-specific epigenomic signature
          (progeroid-related; not present in UVSS) enriched in three categories:
          developmental transcription factors, ion/neurotransmitter membrane
          transporters and synaptic neuro-developmental genes.
        explanation: >-
          Identifies a progeroid-specific DNA methylation signature in CS that
          is absent in UV-sensitive syndrome, supporting an epigenomic mechanism
          for accelerated aging distinct from the shared NER defect.
      - reference: PMID:37688320
        reference_title: "Epigenomic signature of accelerated ageing in progeroid Cockayne syndrome."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          the epigenetic clock returned a marked increase in CS biological age
          respect to healthy and UVSS cells.
        explanation: >-
          Quantifies accelerated biological aging in CS cells using an
          epigenetic clock, providing molecular evidence for the progeroid
          phenotype.
    downstream:
      - target: Accelerated Cellular Senescence
        description: >-
          The CS-specific progeroid epigenomic signature (advanced epigenetic
          age, reprogramming of developmental and synaptic gene programs)
          provides a molecular substrate for accelerated cellular senescence.
        causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - name: Peripheral Demyelinating Neuropathy Susceptibility
    description: >-
      Peripheral nerve involvement is a recognized component of Cockayne
      syndrome, particularly demyelinating polyneuropathy, reflecting
      vulnerability of long-lived myelinating Schwann cells to unrepaired
      transcription-blocking DNA lesions.
    cell_types:
      - preferred_term: Schwann cell
        term:
          id: CL:0002573
          label: Schwann cell
    biological_processes:
      - preferred_term: myelination
        term:
          id: GO:0042552
          label: myelination
    evidence:
      - reference: PMID:36190439
        reference_title: "Peripheral neuropathies associated with DNA repair disorders."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cockayne syndrome has classically been linked to demyelinating
          polyneuropathies, whereas xeroderma pigmentosum has long been
          associated with axonal polyneuropathies.
        explanation: >-
          Supports a characteristic demyelinating peripheral neuropathy profile
          in CS.
  - name: Accelerated Cellular Senescence
    description: >-
      Cockayne syndrome is a segmental progeroid syndrome in which defective
      DNA repair leads to accelerated cellular aging. Oxidative stress and
      autophagy dysfunction contribute to cellular senescence observed across
      multiple organ systems.
    biological_processes:
      - preferred_term: cellular senescence
        term:
          id: GO:0090398
          label: cellular senescence
    evidence:
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Cockayne syndrome (CS) is a segmental progeroid syndrome characterized
          by defects in the DNA excision repair pathway, predisposing to
          neurodegenerative manifestations.
        explanation: >-
          Directly classifies CS as a segmental progeroid syndrome.
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          This study reveals the link between oxidative stress and accelerated
          aging in affected individuals with CS and highlights new biomarkers of
          cellular senescence.
        explanation: >-
          Supports the mechanistic link between oxidative stress and accelerated
          cellular senescence in CS.
phenotypes:
  - category: Neurologic
    name: Microcephaly
    frequency: VERY_FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Microcephaly
      term:
        id: HP:0000252
        label: Microcephaly
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Cockayne Syndrome B (CSB) is a hereditary multiorgan syndrome
          which-through largely unknown mechanisms-can affect the brain where it
          clinically presents with microcephaly, intellectual disability and
          demyelination.
        explanation: >-
          Explicitly names microcephaly as a clinical presentation of CSB.
  - category: Neurologic
    name: Intellectual Disability
    frequency: OCCASIONAL
    diagnostic: true
    phenotype_term:
      preferred_term: Intellectual disability
      term:
        id: HP:0001249
        label: Intellectual disability
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Cockayne Syndrome B (CSB) is a hereditary multiorgan syndrome
          which-through largely unknown mechanisms-can affect the brain where it
          clinically presents with microcephaly, intellectual disability and
          demyelination.
        explanation: >-
          Identifies intellectual disability as a core clinical manifestation in
          CSB.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0001249 | Intellectual disability | Occasional (29-5%)"
        explanation: >-
          Orphadata classifies intellectual disability as occasional (29-5%) in
          Cockayne syndrome. The higher-frequency cognitive phenotype is better
          captured by HP:0001268 (Mental deterioration), which ORPHA classifies
          as Very frequent (99-80%).
  - category: Neurologic
    name: CNS Demyelination
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: CNS demyelination
      term:
        id: HP:0007305
        label: CNS demyelination
    evidence:
      - reference: PMID:39179905
        reference_title: "HiPSC-derived 3D neural models reveal neurodevelopmental pathomechanisms of the Cockayne Syndrome B."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Cockayne Syndrome B (CSB) is a hereditary multiorgan syndrome
          which-through largely unknown mechanisms-can affect the brain where it
          clinically presents with microcephaly, intellectual disability and
          demyelination.
        explanation: >-
          Supports demyelination as a defining neurologic phenotype.
  - category: Neurologic
    name: Progressive Peripheral Demyelination
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Peripheral demyelination
      term:
        id: HP:0011096
        label: Peripheral demyelination
    evidence:
      - reference: PMID:36190439
        reference_title: "Peripheral neuropathies associated with DNA repair disorders."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cockayne syndrome has classically been linked to demyelinating
          polyneuropathies, whereas xeroderma pigmentosum has long been
          associated with axonal polyneuropathies.
        explanation: >-
          Supports the peripheral demyelinating neuropathy phenotype in CS.
  - category: Neurologic
    name: Ataxia
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Ataxia
      term:
        id: HP:0001251
        label: Ataxia
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Various degrees of ataxia and spasticity were cardinal neurologic
          features, with variably combined systemic characteristics.
        explanation: >-
          Identifies ataxia as a cardinal neurologic feature in ERCC6-related CS.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0001251 | Ataxia | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies ataxia as frequent (79-30%) in Cockayne
          syndrome.
  - category: Neurologic
    name: Spasticity
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Spasticity
      term:
        id: HP:0001257
        label: Spasticity
    evidence:
      - reference: PMID:38674442
        reference_title: "Spectrum of ERCC6-Related Cockayne Syndrome (Type B): From Mild to Severe Forms."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Various degrees of ataxia and spasticity were cardinal neurologic
          features, with variably combined systemic characteristics.
        explanation: >-
          Supports spasticity as a common neurologic manifestation in CS.
  - category: Neurologic
    name: Areflexia
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Areflexia
      term:
        id: HP:0001284
        label: Areflexia
    evidence:
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Short stature, enophtalmos, hearing loss, cataracts, cutaneous
          photosensitivity, frequent dental caries, enamel hypoplasia,
          morphological abnormalities of the teeth, areflexia and spasticity
          were included in the clinical diagnostic score as being the most
          statistically relevant criteria.
        explanation: >-
          Validates areflexia as one of the ten most statistically discriminant
          features of CS in the validated Spitz et al. CS diagnostic score
          (95.7% sensitivity, 86.4% specificity).
    notes: >-
      Areflexia is part of the validated 10-item Spitz CS clinical diagnostic
      score, reflecting peripheral nerve involvement and demyelinating
      polyneuropathy.
  - category: Neurologic
    name: Muscle Weakness
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Muscle weakness
      term:
        id: HP:0001324
        label: Muscle weakness
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "physical therapy to prevent contractures"
        explanation: >-
          Recommended use of physical therapy to prevent contractures in CS
          care guidelines reflects underlying progressive motor weakness and
          functional impairment.
    notes: >-
      Muscle weakness is the most common phenotype in the CoSyNH natural
      history cohort, reported in approximately 78% of patients (80/102),
      contributing to progressive loss of motor function and ambulation in
      late-stage disease.
  - category: Neurologic
    name: Intracranial Calcification
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Intracranial calcification
      term:
        id: HP:0430048
        label: Intracranial calcification
    evidence:
      - reference: PMID:20522568
        reference_title: "Neuroimaging in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Hypomyelination, calcifications, and brain atrophy were the main
          imaging features. Calcifications were typically found in the putamen
          and less often in the cortex and dentate nuclei.
        explanation: >-
          Confirms intracranial calcification (with putaminal predominance) as
          a hallmark neuroimaging feature in a genetically confirmed CS cohort.
      - reference: PMID:27643390
        reference_title: "Cockayne syndrome: a diffusion tensor imaging and volumetric study."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cockayne syndrome (CS) is a rare disorder characterized by severe
          brain atrophy, white matter (WM) hypomyelination and basal ganglia
          calcifications.
        explanation: >-
          Reinforces basal ganglia calcifications among the cardinal imaging
          features of CS in a quantitative MRI cohort study.
    notes: >-
      Basal ganglia calcification (predominantly in the putamen) is a hallmark
      neuroimaging finding in Cockayne syndrome, occurring in ~55% of imaged
      patients in the CoSyNH cohort. Calcifications result from chronic tissue
      injury and mineral deposition and are part of the validated
      clinical-radiologic diagnostic score.
  - category: Neurologic
    name: Sensorineural Hearing Impairment
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Progressive sensorineural hearing impairment
      term:
        id: HP:0000408
        label: Progressive sensorineural hearing impairment
    evidence:
      - reference: PMID:29447894
        reference_title: "Cochlear implantation in pediatric patients with Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cockayne Syndrome (CS) is a rare, autosomal recessive disorder
          characterized by a spectrum of phenotypic abnormalities, including
          progressive sensorineural hearing loss (SNHL) that involves both
          peripheral and central components.
        explanation: >-
          Identifies progressive sensorineural hearing loss as an established
          feature of CS, with both peripheral cochlear and central auditory
          components.
      - reference: PMID:29649050
        reference_title: "Temporal Bone Histopathology in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Severe atrophy of the spiral ligament and atrophy of stria vascularis
          and spiral prominence was present.
        explanation: >-
          Provides direct histopathologic evidence of cochlear pathology in CS,
          including severe stria vascularis and spiral ligament atrophy
          underlying the sensorineural hearing impairment.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000408 | Progressive sensorineural hearing impairment | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies progressive sensorineural hearing impairment as
          very frequent (99-80%) in Cockayne syndrome.
    notes: >-
      Progressive sensorineural hearing loss is a well-established feature of
      CS, owing to degeneration of cochlear nerve fibers. Hearing loss is
      reported in approximately 63% of patients in the CoSyNH cohort. Temporal
      bone histopathology shows stria vascularis atrophy and spiral ganglion
      neuronal loss.
  - category: Neurologic
    name: Cerebellar Atrophy
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Cerebellar atrophy
      term:
        id: HP:0001272
        label: Cerebellar atrophy
    evidence:
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0001272 | Cerebellar atrophy | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies cerebellar atrophy as very frequent (99-80%) in
          Cockayne syndrome.
      - reference: PMID:27643390
        reference_title: "Cockayne syndrome: a diffusion tensor imaging and volumetric study."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Total brain volume in CS was reduced by 57%, predominantly in the infratentorial area"
        explanation: >-
          Quantifies severe infratentorial volume reduction supporting
          cerebellar atrophy as a predominant imaging feature.
  - category: Neurologic
    name: Mental Deterioration
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Mental deterioration
      term:
        id: HP:0001268
        label: Mental deterioration
    evidence:
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0001268 | Mental deterioration | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies mental deterioration as very frequent (99-80%)
          in Cockayne syndrome.
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Among 18 individuals who met inclusion criteria, all but one (94.4%)
          experienced at least one symptom of neurocognitive/neuropsychiatric
          decline, with most individuals experiencing at least half of those
          symptoms.
        explanation: >-
          Confirms near-universal neurocognitive decline in adult CS survivors.
  - category: Neurologic
    name: Atypical Behavior
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Atypical behavior
      term:
        id: HP:0000708
        label: Atypical behavior
    evidence:
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000708 | Atypical behavior | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies atypical behavior as very frequent (99-80%) in
          Cockayne syndrome.
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Among 18 individuals who met inclusion criteria, all but one (94.4%)
          experienced at least one symptom of neurocognitive/neuropsychiatric
          decline, with most individuals experiencing at least half of those
          symptoms.
        explanation: >-
          Near-universal neuropsychiatric symptoms in adult CS survivors support
          behavioral abnormalities as a very frequent feature.
  - category: Growth
    name: Cachexia
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Cachexia
      term:
        id: HP:0004326
        label: Cachexia
    evidence:
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0004326 | Cachexia | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies cachexia as very frequent (99-80%) in Cockayne
          syndrome.
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal
          recessive disorder characterized by cachectic dwarfism, nervous system
          abnormalities, and premature aging.
        explanation: >-
          Identifies cachectic dwarfism as a defining clinical characteristic
          of CS.
  - category: Ophthalmologic
    name: Pigmentary Retinopathy
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Pigmentary retinopathy
      term:
        id: HP:0000580
        label: Pigmentary retinopathy
    evidence:
      - reference: PMID:30820731
        reference_title: "Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Diffuse pigmentary retinopathy with macular atrophy was found in
          ultra-wide-field retinography and autofluorescence.
        explanation: >-
          Documents diffuse pigmentary retinopathy with macular involvement in
          genetically confirmed adult CS patients, supporting the
          retinopathy phenotype.
      - reference: PMID:30820731
        reference_title: "Cockayne syndrome in adults: complete retinal dysfunction exploration of two case reports."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Pigmentary retinopathy in CS could translate a wide dysfunction of
          the retina with major affection of external retinal layers of both
          cone and rod cells.
        explanation: >-
          Identifies combined cone and rod system dysfunction underlying
          pigmentary retinopathy and progressive vision loss in CS.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000580 | Pigmentary retinopathy | Very frequent (99-80%)"
        explanation: >-
          Orphadata classifies pigmentary retinopathy as very frequent (99-80%)
          in Cockayne syndrome.
    notes: >-
      Progressive pigmentary retinopathy is a common ophthalmologic feature
      resulting from retinal photoreceptor degeneration with combined cone and
      rod system dysfunction. Peripheral retinal vasculopathy and ellipsoid
      zone abnormalities have also been reported as novel fundus features.
  - category: Ophthalmologic
    name: Optic Atrophy
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Optic atrophy
      term:
        id: HP:0000648
        label: Optic atrophy
    evidence:
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000648 | Optic atrophy | Occasional (29-5%)"
        explanation: >-
          Orphadata classifies optic atrophy as occasional (29-5%) in
          Cockayne syndrome.
    notes: >-
      Optic atrophy develops due to degeneration of optic nerve fibers in the
      context of progressive neurodegeneration.
  - category: Ophthalmologic
    name: Cataracts
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Cataract
      term:
        id: HP:0000518
        label: Cataract
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Congenital cataracts or other structural anomalies of the eye may be present."
        explanation: >-
          Identifies congenital cataracts as a recognized ophthalmologic feature
          of CS type II in the GeneReviews summary.
      - reference: PMID:26204423
        reference_title: "The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          We confirm that the most valuable prognostic factor in CS is the
          presence of early cataracts.
        explanation: >-
          The CoSyNH cohort (n=102) reported cataracts in approximately 46% of
          participants and identified early cataracts (before age 3) as the
          strongest negative prognostic indicator, supporting a frequent and
          clinically important phenotype.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000518 | Cataract | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies cataracts as frequent (79-30%) in Cockayne
          syndrome.
    notes: >-
      Cataracts occur in approximately 46% of CS patients (CoSyNH cohort) and
      may be congenital, particularly in the severe type II form. Cataracts
      diagnosed before age 3 are the strongest negative prognostic indicator,
      with 5-year survival reduced from ~95% to ~60%.
  - category: Dermatologic
    name: Cutaneous Photosensitivity
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Cutaneous photosensitivity
      term:
        id: HP:0000992
        label: Cutaneous photosensitivity
    evidence:
      - reference: PMID:30988227
        reference_title: "[Cockayne Syndrome]."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The clinical features of CS include photosensitivity, a characteristic
          senile face, significant developmental abnormalities, such as short
          stature, underweight, and microcephaly, progressive cachexia, severe
          visual impairment, and sensorineural deafness.
        explanation: >-
          Explicitly lists photosensitivity as a core clinical feature of
          Cockayne syndrome.
      - reference: PMID:30988227
        reference_title: "[Cockayne Syndrome]."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Unlike XP, in CS, skin cancer is not known to occur in areas of skin
          exposed to sunlight.
        explanation: >-
          Confirms that despite photosensitivity, CS patients are not
          predisposed to skin cancers, distinguishing CS from xeroderma
          pigmentosum.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000992 | Cutaneous photosensitivity | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies cutaneous photosensitivity as frequent (79-30%)
          in Cockayne syndrome.
    notes: >-
      Extreme UV sensitivity causing severe sunburns with minimal exposure is a
      hallmark of CS, directly reflecting the TC-NER defect. Unlike xeroderma
      pigmentosum, CS patients are not predisposed to skin cancers.
  - category: Growth
    name: Short Stature (Cachectic Dwarfism)
    frequency: VERY_FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Short stature
      term:
        id: HP:0004322
        label: Short stature
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal
          recessive disorder characterized by cachectic dwarfism, nervous system
          abnormalities, and premature aging.
        explanation: >-
          Supports growth impairment with cachectic dwarfism/short stature as a
          clinical hallmark.
  - category: Growth
    name: Failure to Thrive
    frequency: VERY_FREQUENT
    phenotype_term:
      preferred_term: Failure to thrive
      term:
        id: HP:0001508
        label: Failure to thrive
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          By the time the disease has become fully manifest, height, weight,
          and head circumference are far below the fifth percentile.
        explanation: >-
          Confirms severe postnatal growth and weight deficiency below the
          fifth percentile as a defining clinical feature of fully manifest CS.
    notes: >-
      Severe growth and weight deficiency is a cardinal feature. Children show
      progressive weight and length decline below the 5th percentile.
  - category: Craniofacial
    name: Progeroid Facial Appearance
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Progeroid facial appearance
      term:
        id: HP:0005328
        label: Progeroid facial appearance
    evidence:
      - reference: PMID:30988227
        reference_title: "[Cockayne Syndrome]."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The clinical features of CS include photosensitivity, a characteristic
          senile face, significant developmental abnormalities, such as short
          stature, underweight, and microcephaly, progressive cachexia, severe
          visual impairment, and sensorineural deafness.
        explanation: >-
          Explicitly names "a characteristic senile face" as a clinical feature
          of CS, directly supporting the progeroid facial appearance phenotype.
  - category: Craniofacial
    name: Deeply Set Eyes
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Deeply set eye
      term:
        id: HP:0000490
        label: Deeply set eye
    evidence:
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Short stature, enophtalmos, hearing loss, cataracts, cutaneous
          photosensitivity, frequent dental caries, enamel hypoplasia,
          morphological abnormalities of the teeth, areflexia and spasticity
          were included in the clinical diagnostic score as being the most
          statistically relevant criteria.
        explanation: >-
          Validates enophthalmos (deeply set eyes) as one of the ten most
          statistically discriminant features of CS in a 69-patient diagnostic
          score derivation cohort.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000490 | Deeply set eye | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies deeply set eyes as frequent (79-30%) in
          Cockayne syndrome.
    notes: >-
      Deep-set, sunken eyes (enophthalmos) are a characteristic feature of the
      CS facial gestalt, partly due to loss of subcutaneous fat. Enophthalmos
      is a discriminant feature in the validated Spitz et al. CS diagnostic
      score (10-item; 95.7% sensitivity, 86.4% specificity).
  - category: Neurologic
    name: Tremor
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Tremor
      term:
        id: HP:0001337
        label: Tremor
    evidence:
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Most participants experienced tremors and peripheral neuropathy, with a few experiencing seizures and strokes."
        explanation: >-
          Documents tremor as a near-universal late-stage neurologic
          manifestation in adult CS survivors (15/18, 83.3%).
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "medications for tremor and spasticity as needed"
        explanation: >-
          Indicates tremor as a recognized treatable manifestation in standard
          CS care guidelines.
    notes: >-
      Tremor is reported in approximately 65% of CS patients in the CoSyNH
      pediatric cohort and in 83.3% of adult survivors, often combined with
      cerebellar dysarthria and ataxia.
  - category: Neurologic
    name: Seizures
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Seizure
      term:
        id: HP:0001250
        label: Seizure
    evidence:
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Most participants experienced tremors and peripheral neuropathy, with a few experiencing seizures and strokes."
        explanation: >-
          Identifies seizures as a less frequent but recognized complication
          in adult CS survivors (5/18, 27.8%).
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies seizures as frequent (79-30%) in Cockayne
          syndrome, supporting upgrade from OCCASIONAL.
    notes: >-
      Seizures occur in approximately 23% of CS patients (CoSyNH cohort) and
      in 28% of adult survivors, often in the context of progressive cortical
      injury and cerebral atrophy. Orphadata classifies seizures as frequent
      (79-30%).
  - category: Neurologic
    name: Cerebral Atrophy
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Cerebral atrophy
      term:
        id: HP:0002059
        label: Cerebral atrophy
    evidence:
      - reference: PMID:27643390
        reference_title: "Cockayne syndrome: a diffusion tensor imaging and volumetric study."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Total brain volume in CS was reduced by 57%, predominantly in the infratentorial area"
        explanation: >-
          Quantifies severe brain atrophy (57% volume reduction with
          infratentorial predominance) as a hallmark imaging feature.
      - reference: PMID:38808024
        reference_title: "Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "85.7% had generalized cerebral atrophy on MRI while 78.6% had white matter changes."
        explanation: >-
          Confirms generalized cerebral atrophy on MRI in 85.7% of adult CS
          survivors with available imaging.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0002059 | Cerebral atrophy | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies cerebral atrophy as frequent (79-30%) in
          Cockayne syndrome.
    notes: >-
      Progressive global cerebral atrophy is a near-universal MRI finding,
      with prominent cerebellar and corpus callosum involvement.
  - category: Neurologic
    name: Cerebral Hypomyelination
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Cerebral hypomyelination
      term:
        id: HP:0006808
        label: Cerebral hypomyelination
    evidence:
      - reference: PMID:20522568
        reference_title: "Neuroimaging in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Hypomyelination, calcifications, and brain atrophy were the main imaging features."
        explanation: >-
          Identifies hypomyelination as one of the three principal neuroimaging
          features of CS in a genetically and biochemically confirmed cohort.
      - reference: PMID:27643390
        reference_title: "Cockayne syndrome: a diffusion tensor imaging and volumetric study."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Mean ADC values corresponded to a hypomyelinating disorder."
        explanation: >-
          DTI-based quantitative confirmation that CS white matter
          abnormalities correspond to a hypomyelinating disorder pattern.
    notes: >-
      Diffuse cerebral white matter hypomyelination (leukodystrophy) is part
      of the validated Spitz CS clinical-radiological diagnostic score and
      helps distinguish CS from other childhood leukoencephalopathies.
  - category: Musculoskeletal
    name: Multiple Joint Contractures
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Multiple joint contractures
      term:
        id: HP:0002828
        label: Multiple joint contractures
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Affected children have early postnatal contractures of the spine
          (kyphosis, scoliosis) and joints.
        explanation: >-
          Identifies early postnatal joint contractures as a recognized
          feature of CS, especially in the severe type II form.
    notes: >-
      Joint contractures are reported in approximately 63% of CS patients
      (CoSyNH cohort), reflecting both early postnatal involvement (especially
      in CS type II/COFS) and later progressive limitation of joint mobility.
  - category: Musculoskeletal
    name: Kyphosis
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Kyphosis
      term:
        id: HP:0002808
        label: Kyphosis
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Affected children have early postnatal contractures of the spine
          (kyphosis, scoliosis) and joints.
        explanation: >-
          Confirms kyphosis as a recognized spinal deformity in CS, especially
          in the severe type II form.
    notes: >-
      Kyphosis develops as part of the spinal contracture profile of CS,
      particularly in severe early-onset forms.
  - category: Musculoskeletal
    name: Scoliosis
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Scoliosis
      term:
        id: HP:0002650
        label: Scoliosis
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Affected children have early postnatal contractures of the spine
          (kyphosis, scoliosis) and joints.
        explanation: >-
          Confirms scoliosis as a recognized spinal deformity in CS, especially
          in the severe type II form.
    notes: >-
      Scoliosis is reported in approximately 48% of CS patients (CoSyNH
      cohort) and contributes to progressive musculoskeletal disability.
  - category: Gastrointestinal
    name: Gastroesophageal Reflux
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Gastroesophageal reflux
      term:
        id: HP:0002020
        label: Gastroesophageal reflux
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          treatment of cataracts and other ophthalmologic complications,
          hearing loss, hypertension, and gastroesophageal reflux as in the
          general population
        explanation: >-
          Lists gastroesophageal reflux as a recognized complication requiring
          standard management in CS care guidelines.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0002020 | Gastroesophageal reflux | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies gastroesophageal reflux as frequent (79-30%)
          in Cockayne syndrome.
    notes: >-
      Gastroesophageal reflux is reported in approximately 53% of CS patients
      (CoSyNH cohort) and contributes to feeding difficulties and aspiration
      risk.
  - category: Cardiovascular
    name: Hypertension
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Hypertension
      term:
        id: HP:0000822
        label: Hypertension
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          yearly assessment for complications such as hearing loss, hepatic or
          renal dysfunction, and hypertension.
        explanation: >-
          Identifies hypertension among the recognized late complications of
          CS warranting yearly surveillance per management guidelines.
    notes: >-
      Hypertension is reported in approximately 18% of CS patients in
      surveillance studies and is recommended for annual monitoring per
      GeneReviews management guidelines.
  - category: Dental
    name: Carious Teeth
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Carious teeth
      term:
        id: HP:0000670
        label: Carious teeth
    evidence:
      - reference: PMID:23311583
        reference_title: "A possible cranio-oro-facial phenotype in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Dental caries was associated with enamel defects, a high
          sugar/carbohydrate soft food diet, poor oral hygiene and dry mouth.
        explanation: >-
          Identifies frequent dental caries as a recognized oro-dental feature
          of CS, multifactorial in origin (enamel defects, diet, hygiene, and
          dry mouth).
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Short stature, enophtalmos, hearing loss, cataracts, cutaneous
          photosensitivity, frequent dental caries, enamel hypoplasia,
          morphological abnormalities of the teeth, areflexia and spasticity
          were included in the clinical diagnostic score
        explanation: >-
          Validates frequent dental caries as one of the ten most discriminant
          features in the Spitz et al. validated CS diagnostic score.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0000670 | Carious teeth | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies carious teeth as frequent (79-30%) in Cockayne
          syndrome.
    notes: >-
      Frequent dental caries is part of the validated 10-item CS diagnostic
      score, with multifactorial etiology including enamel hypoplasia, soft
      cariogenic diet, and reduced salivary flow.
  - category: Dental
    name: Enamel Hypoplasia
    frequency: FREQUENT
    diagnostic: true
    phenotype_term:
      preferred_term: Enamel hypoplasia
      term:
        id: HP:0006297
        label: Enamel hypoplasia
    evidence:
      - reference: PMID:23311583
        reference_title: "A possible cranio-oro-facial phenotype in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Various oro-facial and dental anomalies were found: retrognathia;
          micrognathia; high- arched narrow palate; tooth crowding; hypodontia
          (missing permanent lateral incisor, second premolars or molars),
          screwdriver shaped incisors, microdontia, radiculomegaly, and enamel
          hypoplasia.
        explanation: >-
          Documents enamel hypoplasia as one of multiple recognized
          oro-dental anomalies in a 17-patient CS cohort.
      - reference: PMID:33536051
        reference_title: "Diagnostic and severity scores for Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Short stature, enophtalmos, hearing loss, cataracts, cutaneous
          photosensitivity, frequent dental caries, enamel hypoplasia,
          morphological abnormalities of the teeth, areflexia and spasticity
          were included in the clinical diagnostic score
        explanation: >-
          Validates enamel hypoplasia among the ten most discriminant
          diagnostic features of CS.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "HP:0006297 | Enamel hypoplasia | Frequent (79-30%)"
        explanation: >-
          Orphadata classifies enamel hypoplasia as frequent (79-30%) in
          Cockayne syndrome.
    notes: >-
      Enamel hypoplasia is part of the validated CS diagnostic score and
      contributes to caries susceptibility.
  - category: Dental
    name: Hypodontia
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Hypodontia
      term:
        id: HP:0000668
        label: Hypodontia
    evidence:
      - reference: PMID:23311583
        reference_title: "A possible cranio-oro-facial phenotype in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          hypodontia (missing permanent lateral incisor, second premolars or
          molars)
        explanation: >-
          Documents hypodontia (notably missing lateral incisors, second
          premolars, and molars including agenesis of second permanent molars)
          as part of the CS oro-dental phenotype.
    notes: >-
      Hypodontia, including newly reported agenesis of second permanent
      molars, is part of the cranio-oro-facial phenotype of CS.
  - category: Dental
    name: Microdontia
    frequency: OCCASIONAL
    phenotype_term:
      preferred_term: Microdontia
      term:
        id: HP:0000691
        label: Microdontia
    evidence:
      - reference: PMID:23311583
        reference_title: "A possible cranio-oro-facial phenotype in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          screwdriver shaped incisors, microdontia, radiculomegaly, and enamel
          hypoplasia.
        explanation: >-
          Identifies microdontia among the dental morphology anomalies in CS.
    notes: >-
      Microdontia and atypical tooth morphology (e.g., screwdriver-shaped
      incisors) are part of the CS oro-dental gestalt.
  - category: Craniofacial
    name: Micrognathia
    frequency: FREQUENT
    phenotype_term:
      preferred_term: Micrognathia
      term:
        id: HP:0000347
        label: Micrognathia
    evidence:
      - reference: PMID:23311583
        reference_title: "A possible cranio-oro-facial phenotype in Cockayne syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Various oro-facial and dental anomalies were found: retrognathia;
          micrognathia; high- arched narrow palate; tooth crowding
        explanation: >-
          Confirms micrognathia and retrognathia as part of the CS
          cranio-oro-facial phenotype, contributing to mid-face hypoplasia.
    notes: >-
      Micrognathia and retrognathia, with cephalometric mid-face hypoplasia,
      are part of the CS facial gestalt.
genetic:
  - name: ERCC6
    gene_term:
      preferred_term: ERCC6
      term:
        id: hgnc:3438
        label: ERCC6
    association: Pathogenic Variants
    frequency: VERY_FREQUENT
    notes: >-
      ERCC6 (CSB) is the major causative gene, accounting for approximately 75%
      of cases, and is associated with type B disease. CSB is an ATP-dependent
      chromatin remodeler that couples DNA repair to transcription.
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Mutations in the ERCC6 and ERCC8 genes are the predominant causes of
          Cockayne syndrome, with ERCC6 gene mutations present in approximately
          75% of cases.
        explanation: >-
          Supports ERCC6 as the predominant molecular contributor in CS.
  - name: ERCC8
    gene_term:
      preferred_term: ERCC8
      term:
        id: hgnc:3439
        label: ERCC8
    association: Pathogenic Variants
    frequency: FREQUENT
    notes: >-
      ERCC8 (CSA) is the second major causative gene, accounting for
      approximately 25% of cases, and is associated with type A disease.
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Mutations in the ERCC6 and ERCC8 genes are the predominant causes of
          Cockayne syndrome, with ERCC6 gene mutations present in approximately
          75% of cases.
        explanation: >-
          Supports ERCC8 as a principal causative gene in Cockayne syndrome.
inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      Cockayne syndrome classically follows autosomal recessive inheritance due
      to biallelic pathogenic variants in DNA repair genes.
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          BACKGROUND: Cockayne syndrome (CS) is a rare, multisystem, autosomal
          recessive disorder characterized by cachectic dwarfism, nervous system
          abnormalities, and premature aging.
        explanation: >-
          Directly supports autosomal recessive inheritance in CS.
      - reference: ORPHA:191
        supports: SUPPORT
        snippet: "Autosomal recessive"
        explanation: >-
          Orphadata confirms autosomal recessive inheritance for Cockayne
          syndrome.
diagnosis:
  - name: Molecular genetic testing
    description: >-
      Sequencing-based testing (including whole-exome sequencing) is central for
      molecular diagnosis and family counseling in suspected Cockayne syndrome.
    diagnosis_term:
      preferred_term: molecular genetic testing
      term:
        id: MAXO:0000533
        label: molecular genetic testing
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Trio-based whole-exome sequencing (trio-WES) was employed to identify
          potential pathogenic variants associated with CS.
        explanation: >-
          Supports WES-based molecular testing as a practical diagnostic method
          for CS.
  - name: Preimplantation genetic testing for monogenic disease
    description: >-
      PGT-M can be used in affected families to reduce transmission risk of
      pathogenic ERCC6/ERCC8 variants through assisted reproduction.
    diagnosis_term:
      preferred_term: preimplantation genetic testing
      term:
        id: MAXO:0009003
        label: preimplantation genetic testing
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Preimplantation genetic testing for monogenic disorders (PGT-M) was
          conducted to prevent the transmission of the pathogenic variant.
        explanation: >-
          Supports application of PGT-M as a prevention-oriented diagnostic
          strategy in at-risk families.
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The successful application of PGT-M in this family offers a potential
          approach for addressing other monogenic diseases.
        explanation: >-
          Confirms successful clinical application of PGT-M for CS prevention.
treatments:
  - name: Nicotinamide Supplementation
    description: >-
      Nicotinamide has been explored experimentally in CS cellular models to
      reduce inflammatory and oxidative stress abnormalities, enhance autophagy,
      and restore mitochondrial DNA polymerase gamma (POLG1) levels. Clinical
      benefit remains to be established.
    treatment_term:
      preferred_term: nicotinamide supplementation
      term:
        id: MAXO:0000088
        label: dietary intervention
    evidence:
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          The supplementation with nicotinamide adjusted these abnormalities by
          enhancing autophagy and decreasing inflammation.
        explanation: >-
          Supports nicotinamide modulation of oxidative stress and autophagy in
          patient-derived cellular systems.
      - reference: PMID:39611850
        reference_title: "Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          CSA/CSB-dependent depletion of the mitochondrial DNA polymerase-γ
          catalytic subunit (POLG1) was restored following nicotinamide
          supplementation in CS-affected individuals' fibroblasts.
        explanation: >-
          Demonstrates nicotinamide can restore POLG1 levels in CS cells,
          suggesting potential mitochondrial benefit.
  - name: Genetic Counseling
    description: >-
      Genetic counseling is important for recurrence-risk assessment and
      reproductive planning in affected families, including discussion of
      PGT-M options.
    treatment_term:
      preferred_term: genetic counseling
      term:
        id: MAXO:0000079
        label: genetic counseling
    evidence:
      - reference: PMID:39473441
        reference_title: "Preimplantation genetic testing for Cockayne syndrome with a novel ERCC6 variant in a Chinese family."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The findings of this study broaden the variant spectrum of ERCC6 and
          will contribute to the molecular diagnosis and genetic counseling of
          CS.
        explanation: >-
          Directly supports genetic counseling as a core component of clinical
          management.
  - name: Supportive Care
    description: >-
      Multidisciplinary supportive management including strict UV avoidance,
      nutritional support, hearing aids, ophthalmologic monitoring, and
      management of contractures through rehabilitation. No curative therapy
      exists. Yearly surveillance is recommended for hearing loss, hepatic and
      renal dysfunction, and hypertension.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Treatment of manifestations: Feeding gastrostomy tube placement as
          needed; individualized educational programs for developmental delay;
          medications for tremor and spasticity as needed; physical therapy to
          prevent contractures
        explanation: >-
          Documents the multimodal supportive care approach recommended in the
          GeneReviews CS management summary, including feeding support,
          rehabilitation, and symptom-targeted pharmacotherapy.
      - reference: PMID:26204423
        reference_title: "The Cockayne Syndrome Natural History (CoSyNH) study: clinical findings in 102 individuals and recommendations for care."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Using this evidence, we have created simple guidelines for the care
          of individuals with CS.
        explanation: >-
          Establishes the CoSyNH multidisciplinary care guidelines as the
          evidence base for supportive management in CS.
  - name: Photoprotection and Sunlight Avoidance
    description: >-
      Strict avoidance of excessive sun exposure, with consistent use of
      broad-spectrum sunscreens and protective sunglasses for lens and retinal
      protection. UV avoidance is critical given the underlying TC-NER defect
      and severe photosensitivity.
    treatment_term:
      preferred_term: sunlight avoidance
      term:
        id: MAXO:0000055
        label: sunlight avoidance
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          use of sunscreens and limitation of sun exposure for cutaneous
          photosensitivity.
        explanation: >-
          Recommends sunscreens and sun exposure limitation as the cornerstone
          intervention for cutaneous photosensitivity in CS management
          guidelines.
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "use of sunglasses for lens/retina protection"
        explanation: >-
          Supports use of sunglasses for ophthalmologic photoprotection in CS.
  - name: Cochlear Implantation
    description: >-
      Cochlear implantation can be effective for managing progressive
      sensorineural hearing loss in CS pediatric patients, with reported
      improvements in speech perception scores and quality of life. Best
      outcomes are seen in patients with post-lingual hearing loss or better
      cognitive function.
    treatment_term:
      preferred_term: cochlear device implantation
      term:
        id: MAXO:0009025
        label: cochlear device implantation
    evidence:
      - reference: PMID:29447894
        reference_title: "Cochlear implantation in pediatric patients with Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Subjective benefits were noted early after activation in both
          patients, and speech perception scores improved over time as well,
          varying from 42 to 70% (versus 0-12% previously).
        explanation: >-
          Documents quantitative improvements in speech perception following
          cochlear implantation in pediatric CS patients with progressive
          sensorineural hearing loss.
      - reference: PMID:38803843
        reference_title: "Treatment outcomes of cochlear implantation in pediatric patients with Cockayne syndrome type I: a case series."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The study underscores the benefits of cochlear implantation in CS
          patients, especially in patients who are post-lingual or with better
          cognitive function.
        explanation: >-
          Confirms cochlear implantation benefit in additional CS type I
          pediatric cases, identifying post-lingual onset and cognitive
          function as predictors of better outcome.
  - name: Gastrostomy Feeding Support
    description: >-
      Placement of a feeding gastrostomy tube to support nutrition and
      caloric intake, with careful titration to avoid rapid weight gain. This
      is a key supportive intervention given the cachectic dwarfism, feeding
      difficulties, and reflux that are characteristic of CS.
    treatment_term:
      preferred_term: gastrostomy
      term:
        id: MAXO:0001346
        label: gastrostomy
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "Feeding gastrostomy tube placement as needed"
        explanation: >-
          Identifies feeding gastrostomy tube placement as a recommended
          nutritional support intervention in CS care guidelines.
  - name: Aggressive Dental Care
    description: >-
      Proactive and aggressive preventive dental care is essential to
      minimize dental caries, given the multifactorial caries susceptibility
      from enamel hypoplasia, soft cariogenic diet, and reduced salivary
      flow.
    treatment_term:
      preferred_term: dental and oral agent therapy
      term:
        id: MAXO:0000264
        label: dental and oral agent therapy
    evidence:
      - reference: PMID:20301516
        reference_title: "Cockayne Syndrome."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: "aggressive dental care to minimize dental caries"
        explanation: >-
          Identifies aggressive dental care as a recommended preventive
          intervention in CS management guidelines.
notes: >-
  Orphanet definition (ORPHA:191): "Cockayne syndrome (CS) is a multisystem
  condition characterized by short stature, a characteristic facial appearance,
  premature aging, photosensitivity, progressive neurological dysfunction, and
  intellectual deficit."

  Deep research sources:
  research/Cockayne_Syndrome-deep-research-falcon.md (regenerated 2026-04-25 with
  Edison Scientific Literature provider; integrates the CoSyNH natural history
  cohort, Spitz et al. validated diagnostic/severity scores, Koob et al.
  neuroimaging series, and Rajamani et al. adult cognitive decline cohort),
  research/Cockayne_Syndrome-deep-research-openai.md (generated 2026-03-15).
  Estimated prevalence approximately 1 in 250,000 (US); other published
  estimates include ~2.7 per million live births and 1/360,000 in Western
  Europe.

  Agents/circumstances to avoid: metronidazole (recurrent reports of severe,
  sometimes fatal hepatotoxicity in CS — PMID:34768013, PMID:20301516); excess
  sun exposure; growth hormone treatment is not recommended (PMID:20301516).
  Extra vigilance is warranted with opioids and sedatives (PMID:20301516).

📚

References & Deep Research

Deep Research

Falcon ▸

Cockayne Syndrome (CS): Disease Characteristics Research Report

Edison Scientific Literature 57 citations 2026-04-25T17:08:44.662805

Cockayne Syndrome (CS): Disease Characteristics Research Report

Target Disease

Disease name: Cockayne syndrome (CS) (wilson2016thecockaynesyndrome pages 1-2)
Category: Genetic; DNA repair / transcription-coupled repair disorder (vessoni2020cockaynesyndromethe pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 1-2)
MONDO ID: Not retrieved in the available source excerpts; requires external database lookup (not available in the current evidence corpus).

1. Disease Information

1.1 Concise overview (current understanding)

Cockayne syndrome (CS) is a rare, autosomal-recessive multisystem disorder characterized by microcephaly, impaired postnatal growth, and premature pathological aging, with additional frequent manifestations including hearing loss, cataracts, retinal dystrophy, developmental delay, and photosensitivity. (wilson2016thecockaynesyndrome pages 1-2, vessoni2020cockaynesyndromethe pages 1-2)

Quote (abstract-level; primary natural history study): “Cockayne syndrome (CS) is a rare, autosomal-recessive disorder characterized by microcephaly, impaired postnatal growth, and premature pathological aging.” (wilson2016thecockaynesyndrome pages 1-2)

CS is strongly linked to defective transcription-coupled nucleotide excision repair (TC-NER) and/or transcription-associated genome maintenance, and is widely considered both a neurodevelopmental and neurodegenerative condition. (vessoni2020cockaynesyndromethe pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3)

1.2 Key identifiers

Direct identifier evidence for core CS was not present in the retrieved excerpts (e.g., OMIM, Orphanet/ORPHA, MeSH, ICD-10/11, MONDO). This report therefore flags these identifiers as not captured from the retrieved corpus.

However, for the XP–CS complex (Xeroderma pigmentosum–Cockayne syndrome overlap), the following were explicitly provided: - Orphanet (ORPHA): 220295 (XP-CS) (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2) - OMIM: 278730, 278760, 278780, 610651 (XP-CS) (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)

1.3 Synonyms and alternative names

Cockayne syndrome (CS) (wilson2016thecockaynesyndrome pages 1-2)
Cockayne syndrome type I/II/III (clinical severity groupings) (vessoni2020cockaynesyndromethe pages 1-2, spitz2021diagnosticandseverity pages 2-4)
“Xeroderma pigmentosum–Cockayne syndrome complex (XP-CS)” for overlap phenotypes with XP features (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)

1.4 Evidence source type

The disease characterization here is derived from: - Aggregated disease-level resources (large natural history cohort) (wilson2016thecockaynesyndrome pages 2-3) - Clinically confirmed cohorts and scoring-system validations (spitz2021diagnosticandseverity pages 1-2) - Imaging cohorts (koob2010neuroimagingincockayne pages 1-2) - Recent mechanistic/model-system studies (patient-derived fibroblasts; iPSC organoids) (chikhaoui2024supplementationwithnicotinamide pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3) - Clinical trial registry records (NCT01142154 chunk 1, NCT03044210 chunk 1, NCT00001813 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary cause: biallelic pathogenic variants affecting transcription-coupled repair and transcription-associated genome maintenance. - Core causal genes: ERCC6 (CSB) and ERCC8 (CSA) (vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 2-3) - Functional hallmark: patient fibroblasts show marked UV sensitivity with defective recovery of RNA synthesis after UV irradiation—consistent with impaired TC-NER (vessoni2020cockaynesyndromethe pages 1-2)

2.2 Risk factors

Genetic risk: autosomal recessive inheritance; risk is driven by biallelic pathogenic variants in ERCC6/ERCC8 and, in overlap syndromes, select NER genes (vessoni2020cockaynesyndromethe pages 1-2, natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)
Consanguinity/founder effects: not quantified in the retrieved evidence; case reports indicate consanguineous families exist, but population-level founder variant statistics were not retrieved here.

2.3 Protective factors

No validated protective genetic variants or environmental protective factors were identified in the retrieved evidence corpus.

2.4 Gene–environment interactions

The retrieved evidence emphasizes UV-induced transcription-blocking lesions as a mechanistic trigger in cellular assays (UV sensitivity; recovery of RNA synthesis), but it does not provide formal human gene–environment interaction analyses. (vessoni2020cockaynesyndromethe pages 1-2)

3. Phenotypes (clinical spectrum)

3.1 Core phenotypes and frequencies (CoSyNH natural history cohort)

In the CoSyNH cohort (n=102), all participants were microcephalic with severe postnatal growth failure (wilson2016thecockaynesyndrome pages 2-3). Reported phenotype frequencies include: - Muscle weakness: 80/102 (~78%) (wilson2016thecockaynesyndrome pages 2-3) - Hearing loss: 64/102 (~63%); in a subset analysis, 44% had conductive/mixed hearing loss and onset/progression were common through childhood (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 2-3) - Tremor: 66/102 (~65%) (wilson2016thecockaynesyndrome pages 2-3) - Joint contractures: 64/102 (~63%) (wilson2016thecockaynesyndrome pages 2-3) - Gastroesophageal reflux: 54/102 (~53%) (wilson2016thecockaynesyndrome pages 2-3) - Scoliosis: 49/102 (~48%) (wilson2016thecockaynesyndrome pages 2-3) - Cataracts: 47/102 (~46%) (wilson2016thecockaynesyndrome pages 2-3) - Seizures: 23/102 (~23%) (wilson2016thecockaynesyndrome pages 6-8, wilson2016thecockaynesyndrome pages 2-3) - Respiratory disease: 20/102 (~20%) (wilson2016thecockaynesyndrome pages 2-3)

Additional clinical/laboratory abnormalities: - Subcutaneous fat loss: 56% (wilson2016thecockaynesyndrome pages 6-8) - Deranged liver function tests: 63% among those tested (n=71) (wilson2016thecockaynesyndrome pages 6-8) - Brain imaging abnormalities: 83.5% (71/85 imaged) (wilson2016thecockaynesyndrome pages 6-8) - Intracranial calcification: 55% (47/85) (wilson2016thecockaynesyndrome pages 6-8) - White matter changes: 38% (33/85) (wilson2016thecockaynesyndrome pages 6-8)

3.2 Adult/late-stage neurologic phenotype (2024 development)

A 2024 multicenter retrospective cohort of adults with CS who survived beyond age 18 (n=18) reported high late-stage neurologic burden: - Neurocognitive/neuropsychiatric decline: 17/18 (94.4%) (rajamani2024cognitivedeclineand pages 5-9) - Tremor: 15/18 (83.3%); peripheral neuropathy: 13/18 (72.2%) (rajamani2024cognitivedeclineand pages 5-9) - Progressive language decline: 15/17 (88.2%) (rajamani2024cognitivedeclineand pages 5-9) - Seizures: 5/18 (27.8%); stroke/TIA: 4/18 (22.2%) (rajamani2024cognitivedeclineand pages 5-9) - Neuroimaging among those with imaging: diffuse brain atrophy 13/15 (86.7%), white matter changes 12/15 (80.0%), basal ganglia calcifications 11/15 (73.3%) (rajamani2024cognitivedeclineand pages 5-9)

3.3 Phenotype ontology mapping (HPO suggestions; non-exhaustive)

(These are suggested HPO labels for knowledge-base normalization; the retrieved excerpts did not provide HPO IDs.) - Microcephaly; progressive postnatal microcephaly (wilson2016thecockaynesyndrome pages 2-3) - Postnatal growth retardation / failure to thrive (wilson2016thecockaynesyndrome pages 2-3) - Photosensitivity (cutaneous) (wilson2016thecockaynesyndrome pages 3-4) - Cataract (early-onset; bilateral common) (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 9-10) - Sensorineural hearing impairment / hearing loss (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 2-3) - Retinal dystrophy / retinal atrophy (wilson2016thecockaynesyndrome pages 1-2) - Tremor (wilson2016thecockaynesyndrome pages 6-8) - Spasticity; areflexia (used in diagnostic scoring) (spitz2021diagnosticandseverity pages 1-2) - Joint contractures; Achilles tendon contracture (wilson2016thecockaynesyndrome pages 3-4, chen2025clinicalandgenetic pages 1-2) - Gastroesophageal reflux (wilson2016thecockaynesyndrome pages 3-4) - Seizures (wilson2016thecockaynesyndrome pages 6-8) - Leukodystrophy / white matter abnormalities; hypomyelination (koob2010neuroimagingincockayne pages 1-2) - Intracranial calcifications (basal ganglia/putamen) (koob2010neuroimagingincockayne pages 1-2) - Peripheral neuropathy (rajamani2024cognitivedeclineand pages 5-9)

3.4 Quality-of-life impact

The retrieved corpus did not include disease-specific EQ-5D/SF-36/PROMIS statistics. However, the high prevalence of feeding difficulties/GERD, progressive neurologic decline, sensory impairment, and contractures strongly implies major limitations in mobility, communication, and daily activities, especially in later stages. (wilson2016thecockaynesyndrome pages 3-4, rajamani2024cognitivedeclineand pages 5-9)

4. Genetic / Molecular Information

4.1 Causal genes and inheritance

Inheritance: autosomal recessive (vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 1-2)
Main genes: ERCC6 (CSB) and ERCC8 (CSA) (vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 2-3)

4.2 Pathogenic variant types (examples from retrieved evidence)

Loss-of-function classes: nonsense, frameshift, splice-site (ERCC8 examples in case series) (chen2025clinicalandgenetic pages 1-2)
Structural variants/exon deletions: exon deletions reported in ERCC8 case series (chen2025clinicalandgenetic pages 1-2)

Population allele frequencies (gnomAD), detailed ClinVar classifications, and comprehensive variant spectra were not retrievable from the current evidence corpus.

4.3 Modifier genes / epigenetics

No modifier genes or epigenetic biomarkers were explicitly identified in the retrieved evidence.

5. Environmental Information

CS is a genetic disorder. The retrieved evidence highlights UV sensitivity and UV-induced transcription-blocking lesions as a mechanistic trigger in cellular assays rather than an epidemiologic environmental risk factor for disease onset. (vessoni2020cockaynesyndromethe pages 1-2)

6. Mechanism / Pathophysiology

6.1 Canonical mechanism: transcription-coupled repair and transcription stress

Patient fibroblasts exhibit UV hypersensitivity with defective recovery of RNA synthesis after UV irradiation, reflecting impaired TC-NER/transcription-associated repair of transcribed genes. (vessoni2020cockaynesyndromethe pages 1-2)

A mechanistic cascade consistent with retrieved evidence: 1) Transcription-blocking DNA lesions (e.g., UV-induced) stall transcription complexes; 2) defective CSA/CSB-dependent transcription-coupled repair leads to persistent transcription stress; 3) downstream consequences include impaired neurodevelopmental programs and progressive neurodegeneration. (vessoni2020cockaynesyndromethe pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3)

6.2 2024 mechanistic development: neurodevelopmental transcriptomics in iPSC-derived organoids

In CSB-deficient patient-derived neurospheres and cerebral organoids, RNA-seq showed: - Neurospheres: upregulation of VEGFA-VEGFR2 signaling, vesicle-mediated transport, and head-development programs (szepanowski2024cockaynesyndromepatient pages 1-3) - Organoids: downregulation of brain development, neuron projection development, and synaptic signaling (szepanowski2024cockaynesyndromepatient pages 1-3) - Shared metabolic signature: upregulated steroid biosynthesis—specifically the cholesterol biosynthesis branch (szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 19-21)

These findings support CS as both neurodevelopmental and neurodegenerative. (szepanowski2024cockaynesyndromepatient pages 1-3)

6.3 2024 mechanistic development: oxidative stress, NRF2 repression, and NAD biology (nicotinamide study)

In patient-derived fibroblasts, oxidative-stress profiling identified two major altered pathways: activation of arachidonic acid metabolism and repression of the NRF2 pathway. Nicotinamide (NAM) supplementation was reported to “adjust[] these abnormalities by enhancing autophagy and decreasing inflammation,” and to restore CSA/CSB-dependent depletion of POLG1 in fibroblasts. (chikhaoui2024supplementationwithnicotinamide pages 1-2)

Interpretation (expert analysis): these data suggest that impaired genome maintenance in CS may propagate a chronic stress phenotype involving redox imbalance, inflammation, and mitochondrial maintenance defects, which may be partially modifiable in vitro through NAD precursor supplementation; however, the evidence remains exploratory and cell-based. (chikhaoui2024supplementationwithnicotinamide pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 9-11)

6.4 Ontology suggestions

GO biological process (examples): transcription-coupled nucleotide-excision repair; DNA damage recognition; response to UV; RNA polymerase II transcription stress response; autophagy; mitophagy; cholesterol biosynthetic process; synapse organization; neuron projection development (vessoni2020cockaynesyndromethe pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3)
Cell Ontology (CL) candidates (examples): oligodendrocyte (white matter disease), neuron, neural progenitor cell (neurospheres), astrocyte; peripheral Schwann cell (neuropathy) (koob2010neuroimagingincockayne pages 1-2, szepanowski2024cockaynesyndromepatient pages 1-3, rapin2006cockaynesyndromein pages 10-11)

7. Anatomical Structures Affected

7.1 Organ and system level (human evidence)

Central nervous system: hypomyelination/white matter loss, cerebral and cerebellar atrophy, basal ganglia calcifications (putamen prominent), brainstem and corpus callosum involvement (koob2010neuroimagingincockayne pages 1-2, koob2010neuroimagingincockayne pages 7-8)
Eye: cataracts; retinal dystrophy/atrophy (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 1-2)
Ear/auditory system: hearing loss (wilson2016thecockaynesyndrome pages 3-4)
Musculoskeletal: joint contractures; scoliosis (wilson2016thecockaynesyndrome pages 2-3)
Gastrointestinal/nutrition: feeding difficulties and GERD; need for careful enteral feeding management (wilson2016thecockaynesyndrome pages 3-4)
Liver/metabolic: deranged liver function tests in 63% of those tested (wilson2016thecockaynesyndrome pages 6-8)
Respiratory: pneumonia/respiratory ailments highlighted as leading causes of death (vessoni2020cockaynesyndromethe pages 1-2)

7.2 UBERON / GO cellular component suggestions

UBERON examples: brain; cerebral white matter; cerebellum; putamen; retina; lens; cochlea; liver; kidney; skeletal muscle; lung.
GO cellular component examples: nucleus; chromatin; mitochondrion; synapse; endoplasmic reticulum (szepanowski2024cockaynesyndromepatient pages 1-3, chikhaoui2024supplementationwithnicotinamide pages 1-2)

8. Temporal Development (onset and progression)

8.1 Typical onset

CS spans a wide severity spectrum “ranging from severe prenatal onset to mild adult-onset subtypes.” (spitz2021diagnosticandseverity pages 1-2)

8.2 Progression

Progressive neurologic impairment is typical; late-stage adult survivors commonly develop neurocognitive/neuropsychiatric decline, tremor, neuropathy, and sometimes seizures/stroke. (rajamani2024cognitivedeclineand pages 5-9)

9. Inheritance and Population

9.1 Epidemiology (recently used/commonly cited values in retrieved evidence)

Incidence estimate (Western Europe): 2.7 per million live births (wilson2016thecockaynesyndrome pages 8-9)
Incidence estimate (Western Europe): 1/360,000 births (spitz2021diagnosticandseverity pages 1-2)
Prevalence estimate: ~2.7 per million births in Western Europe and Japan (vessoni2020cockaynesyndromethe pages 1-2)

9.2 Prognosis statistics (natural history and prognostic factors)

In CoSyNH (n=102): mean age 11.5 years; 28/102 deceased at analysis with mean age at death 8.4 years (range 17 months–30 years). (wilson2016thecockaynesyndrome pages 2-3)

A key prognostic factor is early cataracts: - Cataracts before age 3 were strongly associated with younger age at death; 5-year survival ~60% with early cataracts vs ~95% without. (wilson2016thecockaynesyndrome pages 9-10)

10. Diagnostics

10.1 Clinical and radiologic patterning

Characteristic imaging patterns include hypomyelination, putaminal/basal ganglia calcifications, and progressive cerebral/cerebellar atrophy; MR spectroscopy often shows elevated lactate and decreased NAA/Cho. This pattern helps differentiate CS from other childhood leukoencephalopathies or calcification syndromes. (koob2010neuroimagingincockayne pages 1-2, koob2010neuroimagingincockayne pages 7-8)

10.2 Validated diagnostic/severity scoring (Orphanet J Rare Dis, 2021)

Spitz et al. developed: - A 10-item clinical diagnostic score (short stature; enophthalmos; hearing loss; cataracts; cutaneous photosensitivity; frequent dental caries; enamel hypoplasia; abnormal tooth morphology; areflexia; spasticity) with 95.7% sensitivity and 86.4% specificity at threshold 8.5. (spitz2021diagnosticandseverity pages 1-2, spitz2021diagnosticandseverity pages 4-5) - A 12-item clinical-radiologic score (adds leukodystrophy and brain calcifications) with 96.2% sensitivity and 96.8% specificity at threshold 15.5. (spitz2021diagnosticandseverity pages 4-5) - A 5-domain severity score (head circumference; growth failure; neurosensorial signs; motor autonomy; communication) for longitudinal tracking. (spitz2021diagnosticandseverity pages 1-2)

10.3 Molecular testing strategy

The CoSyNH group recommends first-line molecular testing of CSA/CSB using DNA obtained from blood/mouthwash/dried bloodspots, minimizing the need for skin biopsy, and notes there is no cure so diagnosis supports prognostic counseling and care coordination. (wilson2016thecockaynesyndrome pages 9-10)

10.4 Functional assays

A key functional hallmark is defective recovery of RNA synthesis after UV irradiation in patient fibroblasts (recovery RNA synthesis-type assays), reflecting TC-NER dysfunction. (vessoni2020cockaynesyndromethe pages 1-2)

10.5 Differential diagnosis (imaging-guided examples)

Koob et al. emphasize that the combined imaging features help distinguish CS from congenital CMV, Aicardi–Goutières syndrome, Pelizaeus–Merzbacher disease, and some mitochondrial disorders. (koob2010neuroimagingincockayne pages 7-8, koob2010neuroimagingincockayne pages 8-9)

11. Outcome / Prognosis

11.1 Survival and life expectancy

Severity-group summaries in reviews commonly cite approximate life expectancy of ~5 years (severe), ~16 years (classical), and >30 years (mild). (vessoni2020cockaynesyndromethe pages 1-2)

Real-world cohort outcome data from CoSyNH: mean age at death 8.4 years (range 17 months–30 years) in the cross-sectional analysis, and early cataracts are a strong negative prognostic indicator. (wilson2016thecockaynesyndrome pages 2-3, wilson2016thecockaynesyndrome pages 9-10)

11.2 Causes of death

Quote (review): “In all cases, pneumonia/respiratory ailments are the most common causes of death.” (vessoni2020cockaynesyndromethe pages 1-2)

12. Treatment

12.1 Current applications and real-world implementation (supportive care)

There is no curative therapy; care emphasizes surveillance and complication management. (wilson2016thecockaynesyndrome pages 9-10)

Key care recommendations from CoSyNH include: - Multidisciplinary follow-up, including hearing/vision surveillance and feeding management (wilson2016thecockaynesyndrome pages 3-4) - Feeding support with careful titration of NG/PEG feeding to avoid rapid weight gain and complications (wilson2016thecockaynesyndrome pages 3-4) - Medication safety: avoid metronidazole due to reports of fatal acute hepatic failure; exercise added caution with opioids/sedatives (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 8-9)

MAXO suggestions (examples): supportive care; nutritional support/enteral feeding; physical therapy; hearing evaluation; cataract monitoring; genetic testing; genetic counseling (wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 9-10).

12.2 Experimental / translational developments (2024)

Nicotinamide supplementation showed partial restoration of stress/antioxidant/autophagy-related signatures and POLG1 depletion in vitro in patient fibroblasts; the authors note additional validation is needed. (chikhaoui2024supplementationwithnicotinamide pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 9-11)
iPSC-derived organoids provide a new platform to study early neurodevelopmental dysregulation and lipid/cholesterol pathway alterations in CSB deficiency. (szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 19-21)

12.3 Clinical trials (registry evidence)

Prodarsan™ (D-mannitol) PK/safety trial: NCT01142154; Phase I/II open-label, single group; n=5; primary endpoint was D-mannitol pharmacokinetics comparing IV Osmitrol vs oral Prodarsan; completed (start 2010-06; completion 2011-02). URL: https://clinicaltrials.gov/study/NCT01142154 (NCT01142154 chunk 1)
Metabolic study (indirect calorimetry): NCT03044210; interventional basic-science metabolic evaluation; planned n=25; terminated for insufficient participants; listed completion 2024-08-01. URL: https://clinicaltrials.gov/study/NCT03044210 (NCT03044210 chunk 1)
NIH DNA repair disorders protocol: NCT00001813; observational prospective protocol including CS, XP, TTD; enrollment 709; completed; updated 2026-04-22. URL: https://clinicaltrials.gov/study/NCT00001813 (NCT00001813 chunk 1)
DNage natural history study: NCT00985413; observational pediatric natural history focusing on growth and hearing; terminated due to sponsor receivership. (NCT00985413 chunk 1)

13. Prevention

Primary prevention for CS is genetic (reproductive) rather than environmental. - Genetic counseling is indicated due to autosomal recessive inheritance and recurrence risk. (wilson2016thecockaynesyndrome pages 1-2) - Preimplantation genetic testing (PGT-M): implemented for an ERCC6-variant family with a successful pregnancy reported (proof-of-feasibility for prevention of transmission in affected families). (nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66)

No proven lifestyle/environmental preventive measures were identified in the retrieved evidence.

14. Other Species / Natural Disease

No naturally occurring Cockayne-syndrome analog in non-human species was identified in the retrieved evidence. (Model-system evidence was primarily human cells and literature references.)

15. Model Organisms / Model Systems

15.1 Patient-derived cellular models (real-world research implementations)

Primary fibroblasts from CS patients used for oxidative-stress profiling and nicotinamide response assays (in vitro). (chikhaoui2024supplementationwithnicotinamide pages 1-2)

15.2 iPSC and organoid models (2024)

CSB-deficient iPSC-derived neurospheres and cerebral organoids used for RNA-seq and pathway analysis of early neurodevelopmental and metabolic dysregulation, highlighting synaptic/neuron projection pathway downregulation and cholesterol biosynthesis upregulation. (szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 19-21)

Structured summary artifact

Topic	Key points (include numbers where available)	Evidence type	Key sources (include DOI/URL and publication date)	Citation IDs
Disease definition and genes	Ultra-rare autosomal recessive multisystem/neurodevelopmental-progeroid disorder with defective transcription-coupled nucleotide excision repair (TC-NER). Main causal genes: ERCC6/CSB and ERCC8/CSA. ERCC6 accounts for ~70–75% of molecularly solved cases in several summaries/cohorts.	Human clinical cohort; review	Vessoni et al., Genet Mol Biol (2020-05), DOI: 10.1590/1678-4685-gmb-2019-0085, https://doi.org/10.1590/1678-4685-gmb-2019-0085; Wilson et al., Genet Med (2016-05), DOI: 10.1038/gim.2015.110, https://doi.org/10.1038/gim.2015.110; He et al., Front Genet (2024-10), DOI: 10.3389/fgene.2024.1435622, https://doi.org/10.3389/fgene.2024.1435622	(vessoni2020cockaynesyndromethe pages 1-2, wilson2016thecockaynesyndrome pages 2-3, nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66)
XP-CS overlap genes	Xeroderma pigmentosum–Cockayne syndrome complex (XP-CS) combines CS neurodegeneration/developmental disease with XP photosensitivity/cancer susceptibility. Reported XP-CS genes: ERCC3/XPB, ERCC2/XPD, ERCC4/XPF, ERCC5/XPG; in a literature series of 43 XP-CS patients, 42 were molecular/biochemical confirmed, with most in XP-G then XP-D groups.	Literature review of human cases	Natale & Raquer, Orphanet J Rare Dis (2017-04), DOI: 10.1186/s13023-017-0616-2, https://doi.org/10.1186/s13023-017-0616-2	(natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)
Epidemiology	Estimated prevalence/incidence figures vary by source: ~2.7 per million births in Western Europe/Japan; 1/360,000 births in Western Europe; some recent clinical reports cite ~1 in 250,000 live births and prevalence 2.5 per million.	Review; diagnostic-score cohort; case series	Vessoni et al. (2020-05) https://doi.org/10.1590/1678-4685-gmb-2019-0085; Spitz et al., Orphanet J Rare Dis (2021-02), DOI: 10.1186/s13023-021-01686-8, https://doi.org/10.1186/s13023-021-01686-8; Chen et al., Front Genet (2025-08), DOI: 10.3389/fgene.2025.1591551, https://doi.org/10.3389/fgene.2025.1591551	(vessoni2020cockaynesyndromethe pages 1-2, spitz2021diagnosticandseverity pages 1-2, chen2025clinicalandgenetic pages 1-2)
Prognosis and survival	Severity groups: type I/classical median life expectancy ~16 y; type II/severe ~5 y; type III/mild >30 y. In CoSyNH (n=102), 28/102 died, mean age at death 8.4 y (range 17 months–30 y). Strongest prognostic marker: cataracts before age 3; ~60% 5-year survival with early cataracts vs 95% without. Pneumonia/respiratory disease is the most common cause of death.	Natural-history cohort; review	Wilson et al. (2016-05) https://doi.org/10.1038/gim.2015.110; Vessoni et al. (2020-05) https://doi.org/10.1590/1678-4685-gmb-2019-0085	(wilson2016thecockaynesyndrome pages 2-3, wilson2016thecockaynesyndrome pages 9-10, vessoni2020cockaynesyndromethe pages 1-2)
Core phenotypes with frequencies	CoSyNH frequencies: muscle weakness 80/102 (~78%); hearing loss 64/102 (~63%); tremor 66/102 (~65%); joint contractures 64/102 (~63%); gastroesophageal reflux 54/102 (~53%); scoliosis 49/102 (~48%); cataracts 47/102 (~46%); seizures 23/102 (~23%); respiratory disease 20/102 (~20%). Additional reported frequencies: subcutaneous fat loss 56%; intracranial calcification 55% (47/85 imaged); white matter changes 38% (33/85); hypertension 18% (12/67); abnormal glucose 13% (6/47).	Natural-history cohort	Wilson et al. (2016-05) https://doi.org/10.1038/gim.2015.110	(wilson2016thecockaynesyndrome pages 3-4, wilson2016thecockaynesyndrome pages 6-8, wilson2016thecockaynesyndrome pages 2-3)
Neuroimaging hallmarks	Hallmark triad: hypomyelination, intracerebral calcifications, progressive brain atrophy. Calcifications often in putamen (15/18 in one cohort), also cortex/sulcal depths and dentate nuclei. Progressive atrophy involves supratentorial white matter, cerebellum, corpus callosum, brainstem. MRS: elevated lactate, reduced NAA and Cho. Findings aid differential diagnosis vs congenital CMV, Aicardi-Goutières, Pelizaeus-Merzbacher disease, and mitochondrial disorders.	Human imaging cohort; pathology review	Koob et al., AJNR (2010-10), DOI: 10.3174/ajnr.a2135, https://doi.org/10.3174/ajnr.a2135; Rapin et al., J Child Neurol (2006-11), DOI: 10.1177/08830738060210110101, https://doi.org/10.1177/08830738060210110101	(koob2010neuroimagingincockayne pages 1-2, koob2010neuroimagingincockayne pages 7-8, koob2010neuroimagingincockayne pages 8-9, koob2010neuroimagingincockayne pages 2-4, rapin2006cockaynesyndromein pages 15-21, rapin2006cockaynesyndromein pages 10-11)
Diagnostic and severity scoring	10-item clinical diagnostic score: short stature, enophthalmos, hearing loss, cataracts, cutaneous photosensitivity, frequent dental caries, enamel hypoplasia, abnormal tooth morphology, areflexia, spasticity. Performance: 95.7% sensitivity, 86.4% specificity at threshold 8.5. 12-item clinical-radiological score (adds leukodystrophy and brain calcifications): 96.2% sensitivity, 96.8% specificity at threshold 15.5. Severity score uses 5 items: head circumference, weight/height, neurosensory signs, autonomy/motor development, communication.	Human molecularly confirmed cohort (n=69 for score development)	Spitz et al. (2021-02) https://doi.org/10.1186/s13023-021-01686-8	(spitz2021diagnosticandseverity pages 1-2, spitz2021diagnosticandseverity pages 4-5, spitz2021diagnosticandseverity pages 2-4)
2024 development: adult late-stage neurologic complications	Adult cohort surviving >18 y (n=18): neurocognitive/neuropsychiatric decline in 17/18 (94.4%); tremor 15/18 (83.3%); neuropathy 13/18 (72.2%); progressive language decline 15/17 (88.2%); seizures 5/18 (27.8%); stroke/TIA 4/18 (22.2%); loss of ambulation 8/18 (44.4%). Imaging among those with data: diffuse atrophy 13/15 (86.7%), white-matter changes 12/15 (80.0%), basal ganglia calcifications 11/15 (73.3%).	Human retrospective multicenter adult cohort	Rajamani et al., Neurol Clin Pract (2024-08), DOI: 10.1212/cpj.0000000000200309, https://doi.org/10.1212/cpj.0000000000200309	(rajamani2024cognitivedeclineand pages 5-9, rajamani2024cognitivedeclineand pages 9-13)
2024 development: iPSC brain organoids / neurospheres	CSB-deficient patient iPSC-derived neurospheres and cerebral organoids showed early dysregulation of VEGFA-VEGFR2 signaling, vesicle-mediated transport, and head development at NPC/neurosphere stage; organoids showed downregulation of brain development, neuron projection development, and synaptic signalling. Shared metabolic signature: upregulated steroid/cholesterol biosynthesis. Supports CS as both neurodevelopmental and neurodegenerative.	Human patient-derived iPSC/organoid transcriptomics (preprint)	Szepanowski et al., bioRxiv (2024-10), DOI: 10.1101/2023.10.17.562706, https://doi.org/10.1101/2023.10.17.562706	(szepanowski2024cockaynesyndromepatient pages 1-3, szepanowski2024cockaynesyndromepatient pages 13-17, szepanowski2024cockaynesyndromepatient pages 19-21, szepanowski2024cockaynesyndromepatient pages 10-13)
2024 development: nicotinamide supplementation	In CS patient fibroblasts, oxidative-stress profiling identified activation of arachidonic acid metabolism and repression of NRF2 pathway. Nicotinamide (NAM) was reported to enhance autophagy, reduce inflammatory signals, increase PRDX3/FOXM1, decrease ALOX12/TNF-α/NF-κB-related markers, and restore POLG1 depletion in fibroblasts. Evidence is exploratory and limited by small sample numbers and cell-model design.	Patient-derived fibroblast in vitro study	Chikhaoui et al., Aging (Albany NY) (2024-11), DOI: 10.18632/aging.206160, https://doi.org/10.18632/aging.206160	(chikhaoui2024supplementationwithnicotinamide pages 1-2, chikhaoui2024supplementationwithnicotinamide pages 9-11, chikhaoui2024supplementationwithnicotinamide pages 2-5, chikhaoui2024supplementationwithnicotinamide pages 8-9)
Trial: Prodarsan	NCT01142154; Phase I/II, open-label, single-group PK/safety study of oral Prodarsan (D-mannitol formulation) in pediatric CS; n=5, completed. Oral dosing TID for 6–8 days with escalation to target dose; compared PK after oral Prodarsan vs IV Osmitrol (mannitol). Primary endpoint: D-mannitol PK; key secondary endpoint: short-term safety/tolerability.	Interventional clinical trial registry	ClinicalTrials.gov, NCT01142154, “Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome” (start 2010-06; primary completion 2010-09; completion 2011-02), https://clinicaltrials.gov/study/NCT01142154	(NCT01142154 chunk 1)
Trial: METABO-CS	NCT03044210; interventional metabolic/basic-science study, University Hospital Strasbourg; planned n=25, status TERMINATED (“pas assez de patients”). Primary endpoint: resting energy expenditure by indirect calorimetry vs Black equation; secondary endpoints included hormonal axes, lactate/pyruvate, respiratory quotient, body composition; included CS patients and sibling controls.	Interventional clinical trial registry	ClinicalTrials.gov, NCT03044210, “Metabolic Study of Cockayne Syndrome” (start 2017-04-04; completion listed 2024-08-01), https://clinicaltrials.gov/study/NCT03044210	(NCT03044210 chunk 1)
Trial/registry: NIH DNA repair disorders protocol	NCT00001813; prospective NIH/NCI observational case-control protocol across DNA repair disorders including CS; 709 participants, status COMPLETED. Objectives relevant to CS: detailed clinical phenotyping, longitudinal follow-up, skin/blood/hair/buccal sampling, DNA-repair and molecular analyses, genotype-phenotype correlation, documentation of cancers/atypical features, counseling/education.	Observational clinical protocol registry	ClinicalTrials.gov, NCT00001813, “Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair...” (start 1999-05-10; completed; updated 2026-04-22), https://clinicaltrials.gov/study/NCT00001813	(NCT00001813 chunk 1)
Trial/registry: DNage natural history	NCT00985413 (alias NCT01230333); observational pediatric natural-history study; estimated n=40; status TERMINATED because DNage entered receivership. Focused on natural progression with emphasis on growth and hearing; primary analytic objective was rate of linear growth over 6 or 12 months depending on age; biospecimens included blood, urine, tissue.	Observational natural-history registry	ClinicalTrials.gov, NCT00985413, “Observational Study to Assess Natural History in Cockayne Syndrome Patients” (2009), https://clinicaltrials.gov/study/NCT00985413	(NCT00985413 chunk 1)

Table: This table condenses the most actionable disease-level evidence for Cockayne syndrome, including genetics, phenotype frequencies, prognosis, diagnostics, recent 2024 mechanistic advances, and key trial records. It is designed for direct use in a structured knowledge base entry.

Notes on evidence gaps (important for knowledge-base curation)

Core CS ontology identifiers (OMIM/ORPHA/MeSH/ICD/MONDO) were not present in the retrieved excerpts; only XP-CS identifiers were explicitly captured. (natale2017xerodermapigmentosumcockaynesyndrome pages 1-2)
PMIDs were not present in the retrieved text excerpts, so this report cannot provide PMID-tagged citations from within the current evidence corpus.
Carrier frequency, founder variant prevalence, and validated protective factors were not retrievable from the current evidence corpus.

References

(wilson2016thecockaynesyndrome pages 1-2): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(vessoni2020cockaynesyndromethe pages 1-2): Alexandre Teixeira Vessoni, Camila Chaves Coelho Guerra, Gustavo Satoru Kajitani, Livia Luz Souza Nascimento, and Camila Carrião Machado Garcia. Cockayne syndrome: the many challenges and approaches to understand a multifaceted disease. Genetics and Molecular Biology, May 2020. URL: https://doi.org/10.1590/1678-4685-gmb-2019-0085, doi:10.1590/1678-4685-gmb-2019-0085. This article has 64 citations and is from a peer-reviewed journal.
(chikhaoui2024supplementationwithnicotinamide pages 1-2): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.
(szepanowski2024cockaynesyndromepatient pages 1-3): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.
(natale2017xerodermapigmentosumcockaynesyndrome pages 1-2): Valerie A. I. Natale and Hayley M Raquer. Xeroderma pigmentosum-cockayne syndrome complex. Orphanet Journal of Rare Diseases, Apr 2017. URL: https://doi.org/10.1186/s13023-017-0616-2, doi:10.1186/s13023-017-0616-2. This article has 112 citations and is from a peer-reviewed journal.
(spitz2021diagnosticandseverity pages 2-4): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.
(wilson2016thecockaynesyndrome pages 2-3): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(spitz2021diagnosticandseverity pages 1-2): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.
(koob2010neuroimagingincockayne pages 1-2): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.
(NCT01142154 chunk 1): Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome. DNage B.V.. 2010. ClinicalTrials.gov Identifier: NCT01142154
(NCT03044210 chunk 1): Metabolic Study of Cockayne Syndrome. University Hospital, Strasbourg, France. 2017. ClinicalTrials.gov Identifier: NCT03044210
(NCT00001813 chunk 1): Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy. National Cancer Institute (NCI). 1999. ClinicalTrials.gov Identifier: NCT00001813
(wilson2016thecockaynesyndrome pages 3-4): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(wilson2016thecockaynesyndrome pages 6-8): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(rajamani2024cognitivedeclineand pages 5-9): Geetanjali Rajamani, Seth A. Stafki, Audrey L. Daugherty, William G. Mantyh, Hannah R. Littel, Christine C. Bruels, Christina A. Pacak, Paul D. Robbins, Laura J. Niedernhofer, Adesoji Abiona, Paola Giunti, Shehla Mohammed, Vincent Laugel, and Peter B. Kang. Cognitive decline and other late-stage neurologic complications in cockayne syndrome. Neurology Clinical Practice, Aug 2024. URL: https://doi.org/10.1212/cpj.0000000000200309, doi:10.1212/cpj.0000000000200309. This article has 5 citations.
(wilson2016thecockaynesyndrome pages 9-10): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(chen2025clinicalandgenetic pages 1-2): Jing Chen, Wei Su, Dan Gao, Fangfang Liu, Shuang Chen, Wenhan Zhang, Min Peng, Tao Lei, and Hongmin Zhu. Clinical and genetic analysis of ercc8-related cockayne syndrome: hepatic dysfunction as a biomarker, anhidrosis as a rare feature, and rehabilitation outcomes for ankle contractures. Frontiers in Genetics, Aug 2025. URL: https://doi.org/10.3389/fgene.2025.1591551, doi:10.3389/fgene.2025.1591551. This article has 1 citations and is from a peer-reviewed journal.
(szepanowski2024cockaynesyndromepatient pages 19-21): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.
(chikhaoui2024supplementationwithnicotinamide pages 9-11): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.
(rapin2006cockaynesyndromein pages 10-11): Isabelle Rapin, Karen Weidenheim, Yelena Lindenbaum, Pearl Rosenbaum, Saumil N. Merchant, Sindu Krishna, and Dennis W. Dickson. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. Journal of Child Neurology, 21:1006-991, Nov 2006. URL: https://doi.org/10.1177/08830738060210110101, doi:10.1177/08830738060210110101. This article has 167 citations and is from a peer-reviewed journal.
(koob2010neuroimagingincockayne pages 7-8): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.
(wilson2016thecockaynesyndrome pages 8-9): Brian T. Wilson, Zornitza Stark, Ruth E. Sutton, Sumita Danda, Alka V. Ekbote, Solaf M. Elsayed, Louise Gibson, Judith A. Goodship, Andrew P. Jackson, Wee ik Te Keng, Mary D. King, Emma McCann, Toshino Motojima, Jennifer E. Murray, Taku Omata, Daniela Pilz, Kate Pope, Katsuo Sugita, Susan M. White, and Ian J. Wilson. The cockayne syndrome natural history (cosynh) study: clinical findings in 102 individuals and recommendations for care. Genetics in Medicine, 18:483-493, May 2016. URL: https://doi.org/10.1038/gim.2015.110, doi:10.1038/gim.2015.110. This article has 209 citations and is from a highest quality peer-reviewed journal.
(spitz2021diagnosticandseverity pages 4-5): M. A. Spitz, F. Severac, C. Obringer, S. Baer, N. Le May, N. Calmels, and V. Laugel. Diagnostic and severity scores for cockayne syndrome. Orphanet Journal of Rare Diseases, 16:1-10, Feb 2021. URL: https://doi.org/10.1186/s13023-021-01686-8, doi:10.1186/s13023-021-01686-8. This article has 32 citations and is from a peer-reviewed journal.
(koob2010neuroimagingincockayne pages 8-9): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.
(NCT00985413 chunk 1): Observational Study to Assess Natural History in Cockayne Syndrome Patients. DNage B.V.. 2009. ClinicalTrials.gov Identifier: NCT00985413
(nascimento2022neurodegeneraçãonoenvelhecimento pages 46-66): Lívia Luz Souza Nascimento. Neurodegeneração no envelhecimento: lições da síndrome de cockayne. ArXiv, 2022. URL: https://doi.org/10.11606/t.42.2022.tde-15082022-114300, doi:10.11606/t.42.2022.tde-15082022-114300. This article has 0 citations.
(koob2010neuroimagingincockayne pages 2-4): Mériam Koob, Vincent Laugel, M. Durand, H. Fothergill, C. Dalloz, F. Sauvanaud, H. Dollfus, I. Namer, and J. Dietemann. Neuroimaging in cockayne syndrome. American Journal of Neuroradiology, 31:1623-1630, Oct 2010. URL: https://doi.org/10.3174/ajnr.a2135, doi:10.3174/ajnr.a2135. This article has 141 citations and is from a peer-reviewed journal.
(rapin2006cockaynesyndromein pages 15-21): Isabelle Rapin, Karen Weidenheim, Yelena Lindenbaum, Pearl Rosenbaum, Saumil N. Merchant, Sindu Krishna, and Dennis W. Dickson. Cockayne syndrome in adults: review with clinical and pathologic study of a new case. Journal of Child Neurology, 21:1006-991, Nov 2006. URL: https://doi.org/10.1177/08830738060210110101, doi:10.1177/08830738060210110101. This article has 167 citations and is from a peer-reviewed journal.
(rajamani2024cognitivedeclineand pages 9-13): Geetanjali Rajamani, Seth A. Stafki, Audrey L. Daugherty, William G. Mantyh, Hannah R. Littel, Christine C. Bruels, Christina A. Pacak, Paul D. Robbins, Laura J. Niedernhofer, Adesoji Abiona, Paola Giunti, Shehla Mohammed, Vincent Laugel, and Peter B. Kang. Cognitive decline and other late-stage neurologic complications in cockayne syndrome. Neurology Clinical Practice, Aug 2024. URL: https://doi.org/10.1212/cpj.0000000000200309, doi:10.1212/cpj.0000000000200309. This article has 5 citations.
(szepanowski2024cockaynesyndromepatient pages 13-17): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.
(szepanowski2024cockaynesyndromepatient pages 10-13): Leon-Phillip Szepanowski, Wasco Wruck, Julia Kapr, Andrea Rossi, Ellen Fritsche, Jean Krutmann, and James Adjaye. Cockayne syndrome patient ipsc-derived brain organoids and neurospheres show early transcriptional dysregulation of biological processes associated with brain development and metabolism. BioRxiv, Oct 2024. URL: https://doi.org/10.1101/2023.10.17.562706, doi:10.1101/2023.10.17.562706. This article has 16 citations.
(chikhaoui2024supplementationwithnicotinamide pages 2-5): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.
(chikhaoui2024supplementationwithnicotinamide pages 8-9): Asma Chikhaoui, Kouloud Zayoud, Ichraf Kraoua, Sami Bouchoucha, Anis Tebourbi, Ilhem Turki, and Houda Yacoub-Youssef. Supplementation with nicotinamide limits accelerated aging in affected individuals with cockayne syndrome and restores antioxidant defenses. Aging (Albany NY), 16:13271-13287, Nov 2024. URL: https://doi.org/10.18632/aging.206160, doi:10.18632/aging.206160. This article has 1 citations.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Cockayne Syndrome (CS): Disease Characteristics Research Report

Target Disease

1. Disease Information

1.1 Concise overview (current understanding)

1.2 Key identifiers

1.3 Synonyms and alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical spectrum)

3.1 Core phenotypes and frequencies (CoSyNH natural history cohort)

3.2 Adult/late-stage neurologic phenotype (2024 development)

3.3 Phenotype ontology mapping (HPO suggestions; non-exhaustive)

3.4 Quality-of-life impact

4. Genetic / Molecular Information

4.1 Causal genes and inheritance

4.2 Pathogenic variant types (examples from retrieved evidence)

4.3 Modifier genes / epigenetics

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Canonical mechanism: transcription-coupled repair and transcription stress

6.2 2024 mechanistic development: neurodevelopmental transcriptomics in iPSC-derived organoids

6.3 2024 mechanistic development: oxidative stress, NRF2 repression, and NAD biology (nicotinamide study)

6.4 Ontology suggestions

7. Anatomical Structures Affected

7.1 Organ and system level (human evidence)

7.2 UBERON / GO cellular component suggestions

8. Temporal Development (onset and progression)

8.1 Typical onset

8.2 Progression

9. Inheritance and Population

9.1 Epidemiology (recently used/commonly cited values in retrieved evidence)

9.2 Prognosis statistics (natural history and prognostic factors)

10. Diagnostics

10.1 Clinical and radiologic patterning

10.2 Validated diagnostic/severity scoring (Orphanet J Rare Dis, 2021)

10.3 Molecular testing strategy

10.4 Functional assays

10.5 Differential diagnosis (imaging-guided examples)

11. Outcome / Prognosis

11.1 Survival and life expectancy

11.2 Causes of death

12. Treatment

12.1 Current applications and real-world implementation (supportive care)

12.2 Experimental / translational developments (2024)

12.3 Clinical trials (registry evidence)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms / Model Systems

15.1 Patient-derived cellular models (real-world research implementations)

15.2 iPSC and organoid models (2024)

Structured summary artifact

Notes on evidence gaps (important for knowledge-base curation)